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Abstract 
In order to use nanoparticles in biological applications, they need to be coated by a ligand shell 
(called biofunctionalisation) to provide stability in a physiological environment, including 
preventing non-specific binding, and to target the nanoparticle to areas of interest in the 
sample. One approach to synthesising ligand shells is to self-assemble a monolayer of small 
ligands on the surface of the nanoparticle. The ligand can be considered to consist of a ‘head’, 
‘stem’ and ‘foot’. The ‘foot’ serves to anchor the ligand to the surface of the nanoparticle and, 
with the ‘stem’, drive self-assembly of the shell and seal off the core material from the 
environment. The environment is only exposed to the ‘head’ at the distal end of the ‘stem’. 
While the ‘stem’ and ‘head’ groups could be easily transposed to many different kinds of 
nanoparticles, the ‘foot’ must be adapted according to the surface properties of the 
nanoparticle.  This approach has hitherto been successful with noble metal nanoparticles. In 
this thesis, it is tested with nanoparticles of very different materials: semiconductor 
nanoparticles or quantum dots (QDs) and superparamagnetic iron oxide nanoparticles 
(SPIONs). 
QDs are particularly useful for optical imaging due to their fluorescent properties, such as 
resistance to photobleaching, which give them important advantages over organic 
fluorophores.  QDs have, therefore, been used to screen different ligand shells with a thiol as 
the “foot” and ethylene glycol (EG) as the “head”. A novel protocol, using EG alkanethiol 
ligands to biofunctionalise QDs, has been developed. These EG alkanethiol capped QDs are 
highly stable and soluble in physiological conditions according to a series of increasingly 
stringent stability tests. Crucially, they do not exhibit non-specific binding to cells and a 
controlled number of a specific recognition function can be introduced within the shell for 
targeting. These QDs have been used in live cell imaging. QDs monovalently functionalised 
with Tris-nitrilotriacetic acid (Tris-NTA) have been stoichiometrically coupled to fibroblast 
growth factor 2 (FGF2).  The QDs allow direct visualisation of the interaction of FGF2 with its 
receptors on the surface of living cells. 
The approach has then been transposed to SPIONs. SPIONs, because of their magnetic 
properties, are particularly attractive materials for enhancing magnetic resonance imaging 
contrast in a variety of in vivo situations. The thiol “foot” of EG alkanethiol would not bind well 
to iron oxide, but phosphates bind strongly. Therefore, a new ligand was synthesised, in which 
a phosphoserine was placed at the foot on the ligand, to produce an EG alkane phosphoserine. 
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A ligand exchange protocol was developed, which allowed capping of the SPIONs with this 
ligand.  The resulting EG alkane phosphoserine capped SPIONs were, like the QDs, found to 
possess excellent stability in a series of tests of increasing stringency.  The ligand shell also 
provided good protection of the SPION core against chelation by citrate at acid pH.  
The work presented in this thesis thus describes important advances in the mobilisation of the 
remarkable properties of nanoparticles for biology and medicine.  Firstly, by directly 
synthesising small, highly stable QDs that can be stoichiometrically functionalised for imaging.  
Secondly, by synthesising the first ligand shell for SPIONs that provides sufficient stability to 
allow these materials to be used in experiments where longer term imaging is required, such 
as tracking transplanted stem cells in vivo. Thirdly, the strategy of synthesising ligand shells of 
small molecules that self assemble on the surface of nanoparticles has been extended to 
materials other than the noble metals. This aspect of the thesis highlights that this strategy is 
generic and, if a suitable “foot” unit can be identified, likely to be applicable to nanoparticles 
of any material. 
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Chapter 1 
Introduction 
1.1 Overview 
In this brief introduction, only the strategy behind the work presented in this thesis is 
described. Details of the nanomaterials, their properties and interactions with biological 
systems have been published in a major review recently (Taylor et al. 2012; Appendix I). 
1.2 Opportunities for the use of nanomaterials in biological applications 
Nanobiotechnology is a rapidly emerging field of interdisciplinary science and the use of 
nanomaterials as tools in biological and medical problems is becoming increasingly common. 
Many different areas of opportunity exist and nanoparticles have been developed for many 
different biological applications. One field of application, and the one on which this thesis will 
concentrate, is as labels or contrast enhancing agents for biological imaging (Tong et al. 2009, 
Qiao et al. 2009, Byers & Hitchman 2011, Xu et al. 2012), but others include delivery of drugs 
(Chertok et al. 2008, Singh & Lillard 2009, Wang et al. 2011) and other biological molecules 
(Medarova et al. 2007, Zhong et al. 2010), tumour eradication (Huang & El-Sayed 2010, Silva et 
al. 2011), and biosensing and detection (Dyadyusha et al. 2005, Sée et al. 2009). It is important 
to note that while the term ‘nanoparticle’ can refer to any particle with dimensions below 1 
µm, in these particular instances, it usually, but not always, refers to particles less than 100 
nm, as these offer properties that are unique from the bulk materials (The Royal Society & The 
Royal Academy of Engineering 2004).  
The choice of nanoparticle core largely depends on their intended application, as they all 
impart their own individual chemical and physical properties. For example, quantum dots 
(QDs) are widely used in cell imaging applications, due to their fluorescent properties, which 
enable imaging with standard biological techniques such as epifluorescence and confocal 
microscopy. Furthermore, they can be used to purify cells with particular biomarkers by 
conjugating the QDs to the marker of interest and then separating them out using 
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Fluorescence Activated Cell Sorting (FACS). Superparamagnetic nanoparticles, such as those of 
iron oxide can be used to enhance the contrast of images acquired in vivo by magnetic 
resonance imaging (MRI), due to their magnetic properties. This magnetism may also be 
exploited in order to separate out proteins and other small molecules that specifically attach 
to functional groups on the iron oxide nanoparticle surface from mixtures in solution, by the 
simple application of a strong magnet. Gold is the material of choice for nanoparticles used in 
photothermal therapy of cancer cells due to their ability to produce local heating and damage 
cancerous tissue upon excitation at their surface plasmon resonance (Huang & El-Sayed 2010). 
Recently, there has been some interest in the development of hybrid nanoparticles that have 
cores composed of a combination of materials in order to impart the properties of both and 
increase their functionality. This could include nanomaterials composed of both gold and iron 
oxide, so that MRI imaging of cancer cells can be paired up with their eradication by 
photothermal therapy, or combining iron oxide nanoparticle cores with porous silica 
impregnated with anti-cancer agents for in vivo imaging and drug delivery (Sailor & Park 2012 
and references therein). 
1.3 Interaction of nanoparticles with biological systems 
For some biological applications, imaging included, the implications of the core materials of 
nanoparticles coming into contact with the biological system in question must be considered. 
Biological systems can be particularly volatile environments for nanoparticle core materials. 
Proteins (including enzymes), nucleic acids, hormones, reactive oxygen species and other 
molecules present an array of different functional and chelating groups that would be able to 
interact non-specifically with the surface of the nanoparticle. Furthermore, because of their 
large surface area to volume ratio, nanoparticles provide a substantial platform for the 
adsorption of biological molecules. This creates the possibility of unwanted and unpredictable 
side effects arising due to non-specific interactions. For example, lysozyme and fibrinogen both 
become denatured when adsorbed onto the surface of gold nanoparticles (Zhang et al. 2009, 
Deng et al. 2010) and, while in the case of lysozyme, this resulted only in nanoparticle 
aggregation (no cell work was carried out), denatured fibrinogen induced inflammation in cells 
expressing Mac-1 receptors (Zhang et al. 2009, Deng et al. 2010). Furthermore, binding to the 
surface of iron oxide nanoparticles has been shown to cause the denaturation of human 
transferrin and a loss of functionality of the protein, which could not be recovered even when 
the protein was subsequently separated from the iron oxide nanoparticles (Mahmoudi et al. 
2011). 
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The formation of ‘protein coronas’ around nanoparticle cores in the presence of blood plasma 
(Lundqvist et al. 2008, Lundqvist et al. 2011) and cytosolic fluid (Lundqvist et al. 2011), as well 
as in the presence of serum in cell culture medium (Casals et al. 2010, Casals et al. 2011) has 
already been described. In these studies, proteins adsorbed onto the surface of the 
nanoparticles with varying degrees of strength. Those that were attached less strongly could 
be exchanged by other proteins until the nanoparticle surface was fully populated by strongly 
adsorbed proteins in what is known as a ‘hard protein corona’. Characteristics such as core size 
and surface charge of the nanoparticles can affect the composition of the protein corona by 
influencing which proteins interact with the nanoparticle (Lundqvist et al. 2008, Casals et al. 
2010, Casals et al. 2011, Lundqvist et al. 2011). The adsorption of biological proteins onto the 
surface of nanomaterials has been shown to influence the way in which they are taken up by 
cells (Safi et al. 2011, Lesniak et al. 2012) and, as illustrated by the examples above, 
physiological responses in the organism.  
1.4 Passivation of nanoparticles for use in biological applications 
To avoid the adsorption of native biological molecules to the core of the nanomaterials, the 
surface is passivated by coating with a ligand shell of biocompatible molecules. A multitude of 
different molecules have been used to prepare nanoparticles for biological applications in this 
manner.  Some of the main strategies are summarised below.  
The first two strategies require the exchange of ligands off the surface of the nanomaterials 
that are present as a consequence of the nanoparticle synthesis protocol, but which fail to 
provide suitable passivation. In one strategy, a self-assembled monolayer (SAM) of small 
ligands is formed around the core of the nanoparticle. These small ligands have an anchoring 
moiety for attachment of the ligand to the nanoparticle surface. The classic example is the 
thiol group used with gold nanoparticles (Lévy et al. 2004, Wang et al. 2005, Duchesne et al. 
2008, Gao et al. 2012), inspired by the pioneering work of Whitesides on gold surfaces (1988).  
Thiols are also effective with QDs (Wuister et al. 2003, Al-Hajaj et al. 2011).  In the case of iron 
oxide, the anchoring group could be carboxylic acid (Bourlinos et al. 2002, Vo et al. 2009) or 
dopamine (Xu et al. 2004). These ligands would then be terminated in a hydrophilic moiety, 
which would render them water soluble and biocompatible, such as ethylene glycol. In a 
second strategy, rather than exchanging with small ligands, polymers are used instead. This 
use of polymers as capping agents involves attachment to the nanoparticle core using 
anchoring molecules, of which there is more than one, and hydrophilic terminal groups to 
impart biocompatibility, much like for the small ligands. Polymers that have been used to coat 
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QDs include thiolated poly(maleic anhydride) (Duan et al. 2010) and thiolated poly(ethylene 
glycol) polymers (Derfus et al. 2004, Uyeda et al. 2005, Hu et al. 2006). For iron oxide 
nanoparticles, polymers used include dextran (Berry et al. 2003), chitosan (Li et al. 2008) and 
poly-L-lysine (Arbab et al. 2003).  
Alternatively, rather than ligand-exchange, the stabilising ligands from the nanoparticle 
synthesis may be left intact on the surface of the nanoparticle and amphiphilic molecules 
added.  These arrange themselves around each nanoparticle in a micellar structure, with the 
hydrophobic part of the molecule interacting with the nanoparticle and the hydrophilic end in 
contact with the aqueous environment. Poly(ethylene glycol) phospholipids are common 
amphiphiles for use as micellar coatings for QDs (Carion et al. 2007, Dubertret et al. 2002) and 
can be used in combination with other amphiphiles such as the phospholipid 
phosphatidylcholine (Dubertret et al. 2002). Poly(ethylene glycol) phospholipids have also 
been used for iron oxide nanoparticles (Shtykova et al. 2007). Poly(maleic anhydride-alt-1-
octadecane)-PEG has been used for both iron oxide nanoparticles and QDs. (Yu et al. 2007). 
Another strategy is silica encapsulation and this can be carried out in two different ways. The 
first is ligand-exchange of the stabilising ligands with silica molecules and the subsequent 
polymerisation of further silica molecules to form a layer around the nanoparticle core. For 
QDs, this is achieved by adding different silica containing molecules such as 
mercaptopropyltris(methyloxy)silane, aminopropyltris(methyloxy)silane and 
chlorotrimethylsilane in succession to a sample of TOPO coated QDs (Gerion et al. 2001). The 
silica containing molecules line up on the surface of the QDs before becoming covalently 
bonded together in a dehydration reaction. Many layers of these silane containing molecules 
can be built up to give silica coatings of different depths (Gerion et al. 2001). The second 
involves encapsulation of the whole nanoparticle including its stabilising ligands inside a silica 
shell, which acts as a micellar structure (Huang et al. 2012). Thin silica coatings (1 nm) have 
been achieved for iron oxide nanoparticles by preparing them in microemulsions (Santra et al. 
2001). Gold nanoparticles have been coated in silica using tetraethyl orthosilicate sols (Lu et al. 
2002). 
Although each of these approaches has its merits, for imaging applications, a SAM of small 
ligands is the most suitable option. The resulting nanoparticles have a small hydrodynamic 
radius, as the small ligands won’t cause a large increase in the size or change the shape of the 
nanomaterials. Furthermore, because synthesis of the ligand shell is independent of the 
synthesis of the core of the nanomaterials, this allows the opportunity to optimise the ligand 
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shell for biostability separately. The SAM of small ligands also allows functionalisation to be 
carried out independently from stabilisation by incorporating functional ligands into the ligand 
shell only when the ligand shell has been optimised. 
1.5 Ligand-exchange on hydrophobic nanoparticles 
As previously discussed, when nanoparticles are synthesised, they are typically coated in 
stabilising ligands as a byproduct of the synthesis protocol. For QDs and superparamagnetic 
iron oxide nanoparticles (SPIONs), the solvents used in the synthesis and, therefore, the 
stabilising ligands, are organic. 
For example, a standard technique for preparation of high quality QDs with narrow size 
distributions and comparable surface chemistry in an organic solvent under high temperatures 
has been described (Murray et al. 1993). The technique showed that, by controlled heating 
throughout the reaction, monodisperse samples of 1.5-11.5 nm QDs could be obtained. The 
appropriate temperature of the mixture was identified by studying the absorption spectra of 
QDs over time to determine the size of the QDs and the level of monodispersity in the sample. 
Monodispersity was maintained by reducing the temperature just before the sample became 
too polydisperse and larger QDs were obtained by increasing the temperature if the size of the 
QDs stayed the same between successive analyses by absorption spectroscopy (Murray et al. 
1993). In this method, tri-n-octylphosphine oxide (TOPO) was added to a container kept at a 
reduced pressure and the temperature was maintained at 200˚C. After twenty minutes, the 
temperature was increased to 300˚C and the pressure was raised to atmospheric with argon. 
Two reactants were made up, the first of which was composed of the cadmium precursor, 
dimethylcadmium, and tri-n-octylphosphine (TOP) and the second of which was composed of 
trioctylphosphine selenide (TOPSe) and TOP. After mixing, they were both added to the TOPO 
container, which had previously been taken away from the heat source and was being stirred. 
Nucleation could be observed by cooling of the contents of the container to 180˚C and a colour 
change to yellow/orange. The container was then slowly reheated to between 230 and 260˚C, 
producing CdSe QDs with TOP/TOPO as the ligand (Murray et al. 1993). 
In the case of (SPIONs), the most monodisperse nanomaterials are achieved by thermal 
decomposition. In one method, iron chloride and sodium oleate were reacted to give iron 
oleate, which was heated in a solvent to produce oleic acid capped iron oxide nanoparticles. 
Nucleation and growth of the nanoparticles were influenced by temperature and the final size 
of the nanoparticles influenced by the boiling points of the solvents used (Park et al. 2004). 
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It is possible to make hydrophilic QDs and SPIONs directly (Rogach et al. 2000, Kang et al. 
1996), although the nanoparticles produced are often not of the same quality as those 
produced in organic solvents. Gold nanoparticles, on the other hand, can be produced directly 
into aqueous solutions to give particles stabilised by weakly attached citrate ligands (Turkevich 
et al. 1951).  
Irrespective of the method of synthesis or whether the nanoparticles produced are 
hydrophobic or hydrophilic, they must still undergo ligand-exchange with biocompatible 
capping ligands for them to be suitable for biological applications.  
Ligand-exchange with any biocompatible molecule can be a challenge. The incoming ligand 
must be designed so that it has a greater affinity for the nanoparticle surface than the 
outgoing ligand for the initial displacement to occur and so that the outgoing ligand does not 
reattach to the surface. The incoming ligand must be at a sufficient concentration to allow 
dense packing of the incoming ligand, to minimize the number of defects in the SAM, which 
would expose the nanoparticle core (Duchesne, 2008). A corollary is that sufficient outgoing 
ligand must be removed from the surface to allow full colonisation of the nanoparticle core. 
Finally, the phase transfer between organic and aqueous must be performed in such a way 
that the nanoparticles do not aggregate irreversibly during the ligand-exchange protocol. 
1.6 Aims of the thesis 
The aim of this thesis is to find out whether SAMs of small ligands can provide suitable 
stabilisation and biocompatibility to nanoparticles other than gold and silver, which is where 
most of the work with such ligands has been carried out. An allied question is whether there is 
a general principle for SAMs of small ligands? These two questions will be answered by testing 
the stability of QDs coated in a SAM of small ligands in a ligand-exchange reaction (Fig 1.1) and 
determining their applicability to a substantial biological problem. QDs are a good choice for 
this screening process, because success will be easy to follow due to their fluorescent 
properties. QDs are not yet fully mainstream for use in biological applications due to their 
composition with cytotoxic elements. This will determine if SAMs are sufficient for eliminating 
the toxicity associated with cadmium ions. To find if there is a general principle for SAMs of 
small ligands, a SAM ligand shell will then be transposed to SPIONs to see if, by simply 
changing the anchoring molecule of the small ligand, the rest of the ligand is suitable for 
stabilisation of a different nanomaterial. If this is so, small ligands could be designed for 
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different nanomaterials by keeping the same terminal groups, but only changing the anchoring 
molecules to suit each material. 
 
 
Figure 1.1. Schematic diagram of the transition of nanoparticles from organic stabilising 
ligands in organic solvent to nanoparticles passivated with a SAM of small ligands in water 
via ligand-exchange. 
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Chapter 2 
Development of Versatile Small CdSe/ZnS 
Quantum Dots (QDs) for Biological Imaging 
2.1 Overview 
This chapter discusses the optimisation of a ligand-exchange protocol with EG alkanethiol 
ligands to produce QDs that are water soluble and stable. It consists of results relating to the 
optimisation  of ligand-exchange that will not be published (Sections 2.2, 2.3 and 2.5), but 
which are pertinent to the methodology and a manuscript that is to be submitted to ACS Nano 
of the finalised ligand-exchange protocol and the applications of the QDs to biological 
problems (Section 2.4). 
2.2 Materials and Methods 
These correspond to specific materials and methods not described in Section 2.4. 
2.2.1 Materials 
Lumidot ™ CdSe/ZnS QDs in toluene that are capped with hexadecylamine (HDA) and 
trioctylphosphine oxide (TOPO) and emit at 610 nm were purchased from Sigma-Aldrich 
(Dorset, UK). The CVVVT-ol modified peptide, where T-ol is a threoninol, was purchased from 
Anaspec (Anaspec Inc., San Jose, CA). Hydrophobic CdSe/ZnS QDs powder that are capped with 
TOPO and emit at 610 nm were purchased from PlasmaChem (PlasmaChem GmbH, Berlin, 
Germany). CdSe/ZnS QDs powder capped with HDA and TOPO ligands and that emit at 610 nm 
were purchased from American Elements (Los Angeles, California, USA). CdSe/ZnS QDs powder 
that are capped with octadecylamine (ODA) and that emit at 610 nm were purchased from 
Ocean NanoTech (Ocean NanoTech LLC, Springdale, Arkansas, USA). CdSe/ZnS QDs solution in 
toluene and capped with ODA, which absorbed at 600 nm, were purchased from NN-Labs 
(Nanomaterials and Nanofabrication Laboratories LLC, Fayetteville, Arkansas, USA). 
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2.2.2 Optimisation of a protocol to exchange HDA/TOPO ligands on Lumidot™ QDs for EG 
alkanethiol, HS-(CH2)11-EG4-OH 
Different stages of the ligand-exchange protocol were optimised to give the most stable EG 
alkanethiol capped QDs. These stages and the order in which they were tested can be seen 
below (Fig. 2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Flowchart showing the steps of the ligand-exchange protocol that were optimised 
and the order in which they were tested, indicated by the Roman numerals. 
 
Lumidot™ QDs in toluene with 
HDA/TOPO ligands 
(iii) Wash with solvent to remove 
excess HDA/TOPO ligands 
(i) Add solvent to act as 
intermediate phase in the transfer 
of QDs from toluene to aqueous 
solution 
(ii) EG alkanethiol ligand added in 
aqueous solution 
(iv) Chloroform washes to remove 
intermediate solvent and excess 
outgoing HDA/TOPO ligands 
Centrifuge QDs to pellet them 
Resuspend in 1 X PBS with EG 
alkanethiol ligand overnight 
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2.2.2.1 Identification of a suitable solvent to use in the intermediate phase in the transfer of 
QDs to aqueous solution 
2.2.2.1.1 Chloroform protocol 
Lumidot™ 610 nm QDs with HDA/TOPO ligands in toluene (5 mg mL-1) were diluted 1:40 in 
chloroform with 1 mM EG alkanethiol ligands. The mixture was vortexed and then placed on a 
rotary mixer for 2 h at room temperature. One volume of 1 X phosphate-buffered saline (PBS; 
140 mM NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl and 1.2 mM KH2PO4, pH 7.4) with 0.2 mM EG 
alkanethiol ligand was then added and the mixture vortexed and left to stand for 5 min. The 
aqueous phase containing the QDs was collected from the top of the microtube and 1 volume 
of 1 X PBS containing 0.01% (v/v) Tween with 1 mM EG alkanethiol ligand added. The QDs 
were sonicated for 30 min before being incubated at 4°C overnight. 
2.2.2.1.2 Tetrahydrofuran (THF) protocol 
Lumidot™ 610 nm QDs with HDA/TOPO ligands in toluene (5 mg mL-1) were diluted 1:40 in 
THF. The mixture was vortexed before 1 volume of 1 X PBS with 1 mM EG alkanethiol ligand 
was added dropwise, vortexing between additions. The mixture was left on a rotary mixer for 2 
h at room temperature. The QDs were then centrifuged for 2 min at 7,000 g and the 
supernatant containing THF and excess HDA/TOPO ligands was removed and discarded. The 
QD pellet was resuspended in 100 µL of 0.2 mM EG alkanethiol ligand in 1 X PBS containing 
0.01% (v/v) Tween and vortexed. The QDs were centrifuged for 2 min at 7,000 g and the 
supernatant placed in a clean microtube. The pellet was resuspended in 200 µL of 0.2 mM EG 
alkanethiol ligand in 1 X PBS containing 0.01% (v/v) Tween. Further centrifugation and 
resuspension steps were performed until no pellet remained after centrifugation, each time 
collecting the supernatant and placing it into a microtube. EG alkanethiol ligand was added to 
the pooled supernatants containing the QDs to give a final concentration of 1 mM and the QDs 
were then incubated overnight at 4°C. 
2.2.2.1.3 Chloroform/THF protocol 
Lumidot™ 610 nm QDs with HDA/TOPO ligands in toluene (5 mg mL-1) were diluted 1:40 in 
chloroform with 1 mM EG alkanethiol ligands. The mixture was vortexed and then placed on a 
rotary mixer for 2 h at room temperature. One volume of 1 X PBS with 0.2 mM EG alkanethiol 
ligand was then added and the mixture, vortexed and left to stand for 5 min. The aqueous 
phase was recovered and 1 volume of THF with 1 mM EG alkanethiol ligand added. The QDs 
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were placed back on the rotary mixer for 2 h. The QDs were then centrifuged for at 7,000 g 
and the supernatant containing THF and excess HDA/TOPO ligands was discarded. The pellet 
was resuspended in 0.2 mM EG alkanethiol ligand in 1 X PBS containing 0.01% (v/v) Tween 
(first 100 µL then 200 µL aliquots) and a series of centrifugation, supernatant collection and 
pellet resuspension steps carried out (Section 2.2.2.1.2)  until no pellet appeared after 
centrifugation. EG alkanethiol was added to the supernatants to give a final volume of 1 mM 
and the QDs were incubated at 4°C overnight. 
2.2.2.1.4 THF/chloroform protocol 
Lumidot™ 610 nm QDs with HDA/TOPO ligands in toluene (5 mg mL-1) were diluted 1:40 in 
THF. The mixture was vortexed before 1 volume of 1 X PBS with 1mM EG alkanethiol ligand 
was added dropwise, vortexing between additions. The mixture was left on a rotary mixer for 2 
h at room temperature. 1 volume of chloroform was added to the mixture and vortexed 
before being left to stand for 5 min to allow the aqueous and organic phases to separate. The 
aqueous phase was collected and half a volume of chloroform and half a volume of 1X PBS 
added.  This was centrifuged for 7 min at 11,000 g and the supernatant was discarded. After 
vortexing and allowing to stand for 5 min, the aqueous phase was again collected and half a 
volume of chloroform and half a volume of PBS added for a second time, vortexed and allowed 
to stand for 5 min. The pellet was resuspended in 1 mM EG alkanethiol in 1 X PBS containing 
0.01% (v/v) Tween and incubated overnight at 4°C. 
2.2.2.2 Identification of a suitable aqueous phase to use during ligand-exchange  
Lumidot™ 610 nm QDs with HDA/TOPO ligands in toluene (5 mg mL-1) underwent ligand-
exchange using the THF/chloroform protocol (Section 2.2.2.1.4), except that different aqueous 
solutions were used to dilute the EG alkanethiol ligand before it was added dropwise to the 
QDs, in the 2nd and 3rd chloroform washes and to resuspend the QD pellet after centrifugation. 
The aqueous solutions that were tested for their suitability in the ligand-exchange protocol 
were double deionised water (dd-H2O), 1 X PBS and 10 X PBS (1.4 M NaCl, 81 mM Na2HPO4, 27 
mM KCl and 12 mM KH2PO4, pH 7.4). 
2.2.2.3 Identification of a suitable solvent to wash QDs  
Ten µL of Lumidot™ 610 nm QDs with HDA/TOPO ligands in toluene were placed into 1.5 mL 
microtubes. They were diluted 1/50 using a range of different solvents and were vortexed 
before being transferred into Nanosep centrifugal filtration units and centrifuged at 11,000 g. 
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When between 50 µL and 100 μL of liquid was left above the filter of the Nanosep centrifugal 
filtration units, the filtrate was removed and the liquid above the filter was removed and 
placed in separate microtubes. Both these and the microtube that was used to mix the QDs 
with the solvent were observed under UV illumination to determine where the QDs were. Any 
solvents that were found to allow QDs to stay in solution above the Nanosep centrifugal 
filtration unit filter, but not below the filter or stuck to the microtube used for mixing the QDs 
with the solvent were deemed to be potentially useful.  They were then used to wash the QDs 
by diluting them 1/50 and then concentrating them to 50 µL using a Nanosep centrifugal 
filtration unit before they were used in the THF/chloroform ligand-exchange protocol (section 
2.2.2.1.4). 
2.2.2.4 Identification of the optimal number of chloroform washes to use during the ligand-
exchange protocol 
Lumidot™ QDs underwent ligand exchange using the THF/chloroform protocol (Section 
2.2.2.1.4), except that different numbers of chloroform washes, between 1 and 3, were used 
after the 2 h incubation on the rotary mixer. The first chloroform wash was always with 1 
volume of chloroform, while any subsequent washes were with ½ volume chloroform and ½ 
volume of 1 X PBS. 
QDs were examined after ligand-exchange under UV illumination to identify successful 
protocols. QDs that had successfully undergone ligand-exchange were tested by 
chromatography on Sephadex G25, Sepharose DEAE and CM to identify the protocol that 
produced the most stable QDs (Section 2.4 Materials and Methods). 
2.2.3 Troubleshooting QDs for use in the THF/chloroform ligand-exchange protocol 
Three measurements were discovered to be essential in determining if a batch of QDs would 
be able to undergo successful ligand-exchange:  
(i) The UV-vis absorption spectrum between 450 nm and 750 nm, obtained at room 
temperature using a SpectraMax Plus384 spectrometer. 
(ii) The fluorescence spectrum between 450 nm and 750 nm before ligand-exchange at room 
temperature, obtained with a Cary Eclipse Varian fluorescence spectrophotometer at an 
excitation wavelength of 400 nm. 
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(iii) Transmission Electron Microscopy images of QDs before ligand-exchange (obtained in this 
instance by Dr Humphrey Yiu, Department of Chemistry, University of Liverpool) using an FEI 
Tecnai G2 120 kV Transmission Electron Microscope. 
2.2.4 Identification of QDs suitable for ligand-exchange 
QDs from American Elements, PlasmaChem and Ocean Nanotech were supplied as powders, 
so were suspended directly in THF at 5 mg mL-1. NN-labs QDs were supplied already suspended 
in toluene (5 mg mL-1) and were used as received. Ligand-exchange with EG alkanethiol was 
carried out on QDs from each of the suppliers using the THF/chloroform protocol (section 
2.2.2.1.4). QDs that successfully underwent ligand-exchange were then tested using Sephadex 
G25 chromatography. 
2.2.5 Exchange of HDA/TOPO ligands on Lumidot™ QDs for Mix-matrix ligands 
CVVVT-ol peptidol was dissolved in DMSO:H2O 1:3 (v/v) to give a 4 mM solution. A 10 mM 
stock solution of EG alkanethiol ligand was diluted to give a 4 mM solution in ethanol. Mix 
matrix ligands were then prepared by mixing CVVVT-ol with EG alkanethiol in the ratios 3:7 
and 7:3 (CVVVT-ol:EG alkanethiol v/v), as described for gold nanoparticles (Duchesne et al 
2008). QDs were prepared using the THF/chloroform ligand-exchange protocol (section 
2.2.2.1.4), except that EG alkanethiol ligands were substituted with the appropriate Mix-matrix 
ligands for the second addition of ligand to the QDs. 
 
2.3 Results 
2.3.1 Optimisation of a protocol to exchange HDA/TOPO ligands on Lumidot™ QDs for EG 
alkanethiol, HS-(CH2)11-EG4-OH 
2.3.1.1 Identification of a suitable solvent to use in the intermediate phase in the transfer of 
QDs to aqueous solution.  
When Lumidot™ QDs were received from the supplier, they were coated in a mixture of 
hexadecylamine (HDA) and trioctylphosphine oxide (TOPO) and were soluble in toluene. These 
QDs were tested in a range of ligand-exchange protocols to find the conditions that would 
allow the most efficient removal of HDA and TOPO ligands and recoating with the EG 
alkanethiol, HS-(CH2)11-EG4-OH, thus allowing the transfer of the QDs to aqueous phase. The 
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first step was to find a solvent suitable for use in the intermediate phase of ligand-exchange, 
where both organic and aqueous phases were present. 
       A                   B 
 
 
 
 
Figure 2.2 Exchange of HDA/TOPO ligands on Lumidot™ QDs for EG alkanethiol, HS-(CH2)11-
EG4-OH, using different intermediate phase solvents. Ligand-exchange was carried out on 
Lumidot™ QDs with HDA/TOPO ligands in toluene using four different protocols, each with 
different organic solvents used in the intermediate phases (Section 2.2.2.1). Images of (A) the 
QDs prepared by each of the protocols immediately after ligand-exchange and (B) those QDs 
that underwent successful ligand-exchange after Sephadex G25 chromatography (Section 2.4 
Materials and Methods) were acquired under UV illumination. 
EG alkanethiol capped QDs prepared using the THF protocol (Section 2.2.2.1.2), where THF was 
used in the intermediate phase, and the THF/chloroform protocol (Section 2.2.2.1.4), where 
the THF intermediate phase was followed by a chloroform wash, fluoresced brightly under UV 
illumination and appeared to be dispersed evenly in 1 X PBS after ligand-exchange. However, 
the EG alkanethiol capped QDs from the THF/chloroform protocol appeared to be the brighter 
of the two. On the other hand, the fluorescent intensity of EG alkanethiol capped QDs 
prepared via the chloroform protocol (Section 2.2.2.1.1), where chloroform was used in the 
intermediate phase, and the chloroform/THF protocol (Section 2.2.2.1.3), where a chloroform 
and a THF intermediate phase were used in succession, was much reduced in comparison and, 
furthermore, for the chloroform/THF protocol, a large proportion of QDs were found to have 
come out of solution and were aggregated at the bottom of the microtube (Fig. 2.2A). This 
showed that ligand-exchange with EG alkanethiol ligand was unsuccessful in these last two 
cases. 
The EG alkanethiol capped QDs that appeared to successfully undergo ligand exchange in the 
THF and THF/chloroform protocol were then subjected to Sephadex G25 superfine 
chromatography to assess the integrity of the ligand shell. EG alkanethiol capped QDs 
produced using either protocol passed through the G25 chromatography resin and eluted in 
the excluded volume, V0. This demonstrated that the ligand shell was sufficiently intact as to 
THF 
 
Chloroform 
/THF 
THF/ 
chloroform 
Chloroform 
 
THF 
 
THF/ 
chloroform 
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prevent non-specific binding to the G25 chromatography resin and gave the first indication 
that EG alkanethiol QDs produced by these protocols would be more likely to be resistant to 
non-specific binding when used in biological applications. The QDs in the eluate remained 
brightly fluorescent when examined under UV illumination, again those subjected to the EG 
alkanethiol capped QDs from the THF/chloroform protocol appearing to fluoresce more 
brightly than those from the THF protocol (Fig. 2.2B). 
The intensity of fluorescence of EG alkanethiol QDs from the THF/chloroform protocol both 
after ligand-exchange and after Sephadex G25 chromatography compared to the other organic 
solvents tested indicated that these were the best conditions for ligand exchange, as more 
QDs had been transferred to aqueous solution and there was no large reduction in the 
fluorescence of the QDs. 
2.3.1.2 Identification of a suitable aqueous phase to use during ligand-exchange.  
The effect of electrolytes on the success of ligand-exchange was tested using the 
THF/chloroform protocol and different aqueous solutions for the addition of the EG 
alkanethiol ligand to the QDs (Section 2.2.2.2). When the QDs underwent ligand-exchange with 
dd-H2O as the aqueous phase, the QDs produced had a lower fluorescent intensity compared 
to those that underwent ligand-exchange with PBS, suggesting that some electrolytes are 
needed in the ligand-exchange process. However, those QDs prepared with 10 X PBS were 
noticeably less fluorescent than those prepared with 1 X PBS, thus suggesting that the ligand-
shell of QDs produced at this early stage is not robust enough to allow the QDs to be stable in 
such a high concentration of electrolytes (Fig. 2.3). 
 
 
   
 
 
Figure 2.3 Exchange of HDA/TOPO ligands on Lumidot™ QDs for EG alkanethiol, HS-(CH2)11-
EG4-OH, using different aqueous solutions. Lumidot™ QDs with HDA/TOPO ligands in toluene 
underwent ligand-exchange with THF and then chloroform as the intermediate stages.  
Different aqueous solutions were used for the addition of the EG alkanethiol ligand and to 
resuspend the QD pellet after centrifugation (Section 2.2.2.2). Images of the QDs after ligand 
exchange for each of the aqueous solutions used were acquired under UV illumination. 
dd-H2O 1 X PBS 10 X PBS 
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2.3.1.3 Identification of a suitable solvent to wash QDs before being used in the ligand-
exchange protocol.  
A variety of solvents and mixtures of solvents were tested for their suitability as potential 
washing agents for the QDs received from the supplier. In this way, it was hoped that one 
could be identified that could be used to remove some of the excess HDA and TOPO ligands 
prior to the ligand-exchange protocol being carried out. Of all of the solvents tested, only one 
seemed to be suitable for this use. Dissolving the QDs in toluene caused no attachment of the 
QDs to the sides of the microtube and, in addition, after centrifugation using a Nanosep tube, 
all of the QDs could still be found above the filter. In contrast, for the other solvents tested, 
either QDs were lost by attachment to the microtube or the solvents destroyed the Nanosep 
filter and QDs were found in the filtrate, as well as above the filter (Section 2.2.2.3; Table 2.1). 
 
Table 2.1 Solvents tested for washing QDs to remove excess HDA/TOPO ligands before 
ligand-exchange. Ten μL of QDs were placed into a 1.5 mL microtube and 500 μL of solvent 
added. The QDs were then vortexed before being transferred into a Nanosep centrifugal 
filtration unit and centrifuged at 11,000 g until 50-100 μL of liquid remained above the filter of 
the Nanosep centrifugal filtration unit. Microtubes, filtrate and liquid above the Nanosep filter 
were examined under UV illumination to determine where the QDs were (Section 2.2.2.3). The 
results for each solvent (or combination of solvents) are shown in the table. 
 
SOLVENT 
QDs STUCK TO 
MICROTUBE? 
QDs IN 
FLOWTHROUGH? 
QDs ABOVE 
FILTER? 
Chloroform N Y Y 
DMSO N Y Y 
Methanol Y N N 
Methanol:chloroform 1:9 N Y Y 
Methanol:chloroform 5:5 Y N Y 
Methanol:chloroform 9:1 Y N Y 
Methanol:THF 1:9 N Y Y 
Methanol:THF 5:5 Y N Y 
Methanol:THF 9:1 Y N Y 
THF N Y Y 
Toluene N N Y 
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Figure 2.4 Preparation of EG alkanethiol capped QDs using a toluene wash before the ligand-
exchange protocol. Lumidot™ QDs with HDA/TOPO ligands in toluene were washed by diluting 
them 1/50 in toluene and then centrifuging at 11,000 g in a Nanosep centrifugal filtration unit 
until between 10 µL and 50 μL of liquid remained above the filter. Ligand-exchange with EG 
alkanethiol using THF and then chloroform as the intermediate solvents was then carried out 
(Section 2.2.2.3). Images were acquired under UV illumination of the QDs after ligand-
exchange (A) without the toluene wash and (B) with the toluene wash. 
When the toluene wash was incorporated into the THF/chloroform protocol for ligand-
exchange with EG alkanethiol ligand (section 2.2.2.3), the majority of the QDs that were 
produced were bound to the inside of the microtube or aggregated at the bottom of the tube 
and the QD solution was only dimly fluorescent under UV illumination. In contrast QDs 
prepared via the same THF/chloroform ligand-exchange protocol, but without the toluene 
wash (Section 2.2.2.2.4; Fig. 2.4) were much brighter.  Thus, the toluene wash resulted a much 
lower concentration of EG alkanethiol capped QDs that were soluble in aqueous solution. 
2.3.1.4 Identification of the optimal number of chloroform washes to use during the ligand-
exchange protocol.  
Earlier experiments had indicated that the addition of chloroform washes into the ligand-
exchange protocol after the 2 h incubation on the rotary mixer could result in more efficient 
ligand-exchange with EG alkanethiol ligand (Fig. 2.2). Therefore, this was further examined to 
find the number of chloroform washes that would produce EG alkanethiol capped QDs that 
would pass through Sephadex G25 and would allow QDs to be eluted from Sepharose DEAE 
and CM with either water or a very low concentration of electrolytes (10 mM sodium 
phosphate). EG alkanethiol capped QDs were prepared with 1, 2 or 3 chloroform washes 
(Section 2.2.2.4). 
The QDs prepared using different numbers of chloroform washes all appeared to be very 
bright under UV illumination after ligand-exchange had been carried out (Fig. 2.5A), although 
the QDs did seem to be brighter with increasing numbers of chloroform washes. This was also 
true for the EG alkanethiol QDs after they had been subjected to Sephadex G25 
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chromatography (Fig. 2.5B). QDs prepared with 1, 2 and 3 chloroform washes all eluted from 
the Sephadex G25 chromatography column in V0, but the eluates were brighter for the QDs 
prepared with more chloroform washes. When the QDs were subjected to DEAE anion-
exchange chromatography, however, only those that had been prepared with 3 chloroform 
washes were eluted from the chromatography resin with 10 mM sodium phosphate, while QDs 
prepared with less chloroform washes remain bound to the resin (Fig. 2.5C). EG alkanethiol 
QDs prepared with 3 chloroform washes were then tested with CM cation-exchange 
chromatography and were all washed from the resin with water (Fig. 2.5D). 
          A            B 
    
 
 
 
    C              D 
 
 
 
 
 
 
Figure 2.5 Exchange of HDA/TOPO ligands on Lumidot™ QDs for EG alkanethiol, HS-(CH2)11-
EG4-OH, using different numbers of chloroform washes in the ligand-exchange protocol. 
Ligand-exchange was carried out on HDA/TOPO stabilised Lumidot™ QDs in toluene using THF 
and different numbers of chloroform washes in the intermediate phases (Section 2.2.2.4). 
Images of QDs prepared using 1 chloroform wash (CW1), 2 chloroform washes (CW2) and 3 
chloroform washes (CW3) were acquired under UV illumination (A) directly after ligand-
exchange and (B) after Sephadex G25 chromatography (Section 2.4 Materials and Methods). 
Further images were acquired of (C) the DEAE Sepharose chromatography (Section 2.4 
Materials and Methods) resins after application of QDs prepared with 1, 2 and 3 chloroform 
washes and elution with 10 mM sodium phosphate buffer and (D) the CM Sepharose 
chromatography (Section 2.4 Materials and Methods) resin for QDs prepared with 3 
chloroform washes after elution with water. 
CW1 CW2 CW3 
CW1 CW1 CW2 CW2 
CW3 
CW3 CW3 
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These results showed that the THF/chloroform protocol with THF as the intermediate organic 
solvent, 1 X PBS as the aqueous phase and 3 chloroform washes allowed the most efficient 
ligand-exchange of the HDA/TOPO ligands on Lumidot™ QDs for EG alkanethiol ligands. 
 
                                                                                     C 
 
 
 
 
 
 
 
Figure 2.6 Characterisation of Lumidot™ QDs that failed to undergo successful ligand-
exchange with EG alkanethiol. A new batch of Lumidot™ QDs that consistently failed to 
undergo successful ligand-exchange with EG alkanethiol with THF then chloroform as the 
intermediate phase solvents were characterised via three different methods (Section 2.2.3). 
The (A) UV-vis absorption; (B) fluorescence spectra (excitation wavelength 400 nm) between 
450 nm and 750 nm of the raw materials (with HDA/TOPO ligands in toluene) were obtained; 
(C) TEM imager of the QDs. 
 
2.3.2 Identification of QDs suitable for use in the THF/chloroform ligand-exchange protocol. 
When a new batch of Lumidot™ QDs was received from Sigma Aldrich, the ligand-exchange 
protocol that was previously optimised no longer worked. After ligand-exchange, there were 
no QDs present in the aqueous solution, showing that the EG alkanethiol ligand had been 
unsuccessful at stabilising these QDs. Previous batches of Lumidot™ QDs had looked bright 
orange when the bottle was opened upon receipt, whereas these QDs looked browner in 
colour. Therefore, the QDs were characterised to identify the problem. The UV-vis absorption 
spectrum and the fluorescence spectrum of the raw materials before ligand-exchange were 
obtained to check that the absorbance and emission properties were the same as the previous 
A 
B 
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batch. Although the UV-vis absorption spectrum seemed to be normal, with the maximum 
absorbance at 590 nm, as expected (Fig. 2.6A), the fluorescence spectrum was not as expected 
and displayed an extra peak at 700 nm (Fig. 2.6B). The raw materials were also characterised 
by TEM (Fig. 2.6C) and from this, it was observed that the QDs were rod shaped rather than 
spherical. 
Due to the problems with the new batch of Lumidot™ QDs from Sigma Aldrich, alternative QDs 
were purchased from four different suppliers, so that the best replacement could be found for 
use in the ligand-exchange protocol. Details of the capping ligand used to stabilise the new 
QDs and in what form they were supplied can be found in the table below (Table 2.2). QDs 
from NN-Labs were supplied as a nanoparticle solution and were received from the supplier 
already dissolved in toluene. All other QDs were received in powder form. It was decided to 
dissolve these QDs in THF, since THF was already used as the intermediate phase solvent for 
QDs being used in the ligand-exchange protocol. 
 
Table 2.2 Table of the properties of QDs from four different suppliers that were tested with 
the ligand-exchange protocol.  
 
Like the Lumidot QDs when they were received from Sigma Aldrich, the four new types of QDs 
that were purchased were coated in hydrophobic ligands. They were all tested in the 
THF/chloroform ligand-exchange protocol (Section 2.2.2.1.4) to see which QDs would be most 
stable when the capping ligands were replaced with EG alkanethiol ligands. EG alkanethiol 
capped QDs that were prepared from the American Elements QDs were the least fluorescent 
after ligand-exchange, followed by those prepared from the PlasmaChem QDs and aggregates 
of QDs could be observed in the bottom of the microtubes after ligand-exchange (Fig. 2.7A). 
EG alkanethiol capped QDs prepared from QDs from both Ocean NanoTech and NN-Labs were 
brightly fluorescent after ligand-exchange, with those from NN-Labs being the brighter of the 
two, and no aggregates could be seen at the bottom of these microtubes (Fig. 2.7A). 
SUPPLIER CAPPING LIGANDS SUPPLIED AS... SOLVENT 
American Elements HDA/TOPO Powder THF 
PlasmaChem TOPO Powder THF 
Ocean NanoTech ODA Powder THF 
NN-Labs ODA Solution  Toluene 
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Furthermore, the EG alkanethiol capped QDs prepared from the Ocean NanoTech and the NN-
Labs materials passed through the Sephadex G25 size-exclusion chromatography column and 
were eluted in V0. The NN-Labs QDs in the excluded volume appeared to be more brightly 
fluorescent than those from Ocean NanoTech (Fig. 2.7B). 
From these observations of the QDs after ligand-exchange and the test with Sephadex G25 
size-exclusion chromatography, it was decided that the NN-Labs QDs appeared to be the most 
suitable for use in the ligand-exchange protocol. 
A       B 
                     
 
 
Figure 2.7 Testing QDs from new suppliers with the ligand-exchange protocol. Ligand-
exchange was carried out on the QDs purchased from four suppliers using the THF/chloroform 
ligand-exchange protocol (Section 2.2.2.1.4). Images were acquired under UV illumination of 
(A) the QDs from the four suppliers immediately after ligand exchange and (B) the QDs that 
eluted from the column in the excluded volume, V0, for the QDs that successfully underwent 
ligand-exchange. 
 
2.3.3. Testing a mixed ligand shell on the Lumidot™ QDs.  
Previous work on gold nanoparticles has shown an increased stability of these nanomaterials 
when a Mix-matrix ligand shell (EG alkanethiol and the peptidol, cysteine-valine-valine-valine-
threoninol [CVVVTol]) was used for capping, compared to EG alkanethiol ligands alone 
(Duchesne et al. 2008, Chen et al. 2012). Therefore, this type of ligand shell was tested with 
the Lumidot™ QDs that had previously successfully been coated with EG alkanethiol ligands.  
 
Above left to right: QDs from 
American Elements, PlasmaChem, 
Ocean NanoTech and NN-Labs. 
Above left: QDs from 
Ocean NanoTech. 
Above right: QDs from 
NN-Labs. 
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A  B  
Left to right: EG alkanethiol capped QDs, Mix-matrix 3:7 QDs and Mix-matrix 7:3 QDs 
 
Figure 2.8. Preparation of Mix-matrix capped QDs. QDs were subjected to a ligand-exchange 
protocol where the second load of ligand contained different ratios of EG alkanethiol and 
CVVVTol, to give Mix-matrix capped QDs. QDs with Mix-matrix ligand shells were prepared 
with EG alkanethiol:CVVVTol ratios of 3:7 and 7:3. Pictures were acquired under UV 
illumination of (A) the QDs directly after ligand-exchange and (B) the QD eluates from 
Sephadex G25 size-exclusion chromatography. 
 
Two types of Mix-matrix QDs were prepared using the THF/chloroform protocol with EG 
alkanethiol:CVVVTol ratios of 7:3 and 3:7. When observed under UV illumination after ligand-
exchange, the Mix-matrix-capped QDs had lower fluorescent intensities than the EG 
alkanethiol capped QDs and it appeared that the higher the amount of CVVVTol added, the 
lower the fluorescent intensity (Fig. 2.8A). Furthermore, there was a small pellet of fluorescent 
material at the bottom of the Mix-matrix 3:7 QDs where the QDs had come out of solution and 
were aggregated. This suggested that the QDs were becoming increasingly unstable with 
increased peptidol content. This idea was confirmed when, in fact, very few of the Mix-matrix 
QDs of either ratio went through the G25 resin, shown by an almost complete absence of 
fluorescence in the eluates (Fig. 2.8B). 
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Introduction 
The physical and optical properties of quantum dots (QDs) make these semiconductor 
nanocrystals very exciting to biologists and desirable for use in a variety of applications, 
including optical imaging of biomolecules in cells and in small animals, and biosensing. Their 
resistance to photobleaching, high extinction coefficients and fluorescent quantum yields 
make them particularly bright, while their long fluorescence lifetimes greatly outlive any 
biological autofluorescence, thus allowing improvement of the signal to noise ratio by using 
time-gated imaging (Dahan et al. 2001). Other advantages of QDs are a narrow and size 
tunable fluorescence, and the ability to excite different coloured QDs with one wavelength of 
light allowing multiplexed imaging (Bruchez et al. 1998). Furthermore, their high Stoke’s shift 
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negates the need for filters for detection, since there is no overlap between the wavelength of 
light used to stimulate the QDs and that emitted by them, and the blinking phenomenon 
exhibited by single QDs allows confirmation of the presence of single nanocrystals during 
single molecule imaging and tracking experiments (Dahan et al. 2003, Lidke et al. 2004). 
QDs are usually available as core only or as core/shell nanostructures. The latter entails coating 
the core semiconductor material with another semiconductor material of a wider bandgap, 
which improves the quantum yield of the QDs leading to even brighter nanomaterials. These 
nanomaterials are necessarily small (~2 nm to 8 nm), because their fluorescence depends on 
quantum confinement within the core/shell structure. Their size is comparable to that of 
proteins (~3 nm to 10 nm). Consequently, a QD probe should not perturb biomolecular 
function any more than a fluorescent protein, e.g., GFP. However, the surfaces of QDs are 
quite reactive and will interact with the common functional groups found on biomolecules. 
Thus, before they can be used in biological applications, they must first be passivated. There 
are a number of passivation strategies that have already been used with QDs. However, many 
of these, such as those employing silica encapsulation (Bruchez et al. 1998, Gerion et al. 2001), 
amphiphilic micelles (Carion et al. 2007, Dubertret et al. 2002), polymers and proteins 
(Goldman et al. 2005), cause a large increase in the hydrodynamic radius of the QD, which 
largely negates one important advantage of the starting nanomaterial, namely its small size. 
Such large QD probes may encounter significant steric effects in the crowded macromolecular 
environment of a cell. The alternative approach is to use a self-assembled monolayer (SAM) of 
small ligands (Dubois et al. 2007, Pong et al. 2008, Yeh et al. 2011). This has met with 
considerable success with noble metal nanoparticles (Duchesne et al. 2008), where SAMs ~1 
nm thick have been shown to impart exceptional colloidal stability and resistance to non-
specific binding of biomolecules, as well as allowing a precise stoichiometric functionalisation 
with biomolecules. 
Here, we have designed a ligand-exchange protocol that effectively transfers QDs from organic 
solvent to aqueous solution and assembles a thin, yet very robust ligand shell around the QDs. 
We demonstrate how the same ligand shell can be manipulated to produce QDs that present 
different functional moieties that can act as linker molecules for the conjugation of proteins 
and the monofunctionalisation of the QDs for use in single molecule imaging and tracking 
applications. 
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Materials and Methods 
Materials. The ethylene glycol (EG) terminated alkanethiol, HS-(CH2)11-EG4-OH, and the 
carboxyl terminated EG alkanethiol, HS-(CH2)11-EG4-OCH2-COOH, were purchased from 
Prochimia (ProChimia Surfaces Sp. z o.o, Sopot, Poland). The tris-nitrilotriacetic acid (Tris-NTA) 
terminated EG alkanethiol, HS-(CH2)16-EG3-Tris-NTA  (Valiokas et al. 2008), was a gift from R. 
Tampé (Johann Wolfgang Goethe University, Frankfurt, Germany). CdSe/ZnS QDs in toluene 
that are capped with octadecyl amine (ODA) and that absorb at 600 nm were purchased from 
NN-Labs, LLC (Fayetteville, Arkansas, US). The biotinylated peptide Biotin-GAAHHHHHH, 
Tween-20, bovine serum albumin (BSA), biotin and Ultima Gold™ were purchased from Sigma-
Aldrich Co. Ltd. (Dorset, UK). Tetrahydrofuran (THF; 99.9% purity) was purchased from Fisher 
Scientific UK (Loughborough, UK). Chloroform (99-99.4% purity) was from BDH Lab Supplies 
(Poole, UK) and ethanol (99.8% purity) was from Fluka Chemika (Buchs, Switzerland). Nanosep 
centrifugal ultrafiltration devices (10 kDa and 100 kDa) were purchased from PALL (PALL Corp., 
Portsmouth, Hants, UK). Sephadex G-25 superfine, diethylaminoethyl (DEAE) Sepharose Fast 
Flow and carboxymethyl (CM) Sepharose Fast Flow were purchased from GE Healthcare (Little 
Chalfont, Bucks, UK). Strep-Tactin Sepharose was purchased from IBA (Göttingen, Germany). 
Recombinant human fibroblast growth factor 2 (FGF2) with an N-terminal hexahistidine tag 
was expressed in E. Coli and purified exactly as described (Duchesne et al. 2008). Heparin 
agarose and 10 mL Poly-Prep chromatography columns were purchased from Bio-Rad 
Laboratories Ltd. (Hemel-Hempstead, Herts, UK). Dithiothreitol (DTT) was purchased from 
Sigma-Aldrich (Dorset, UK). Twenty four well tissue culture plates and 384 well assay plates 
were from Corning (Lowell, US). Tritiated thymidine was obtained from ICN Pharmaceuticals 
Ltd. (Basingstoke, UK). Iwaki glass bottomed dishes were purchased from Appleton Woods 
(Selly Oak, Birmingham, UK). Sodium tetraborate decahydrate, streptavidin and neutravidin 
were purchased from Sigma-Aldrich (St. Louis, Missouri). 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) was from Thermo Scientific 
(Barrington, Illinois, US). mPEG-Succinimidyl Valerate (MW 5,000) and mPEG-Biotin (MW 
5,000) were from LaysanBio Inc. (Arab, Alabama, US). N-(2-aminoethyl)-3-
aminopropyltrimethoxysilane was purchased from United Chemical Technologies Inc (Bristol, 
Pennsylvania, US). Tubulin protein (>99% pure), fluorescent HiLyte488 tubulin protein, and 
biotinylated tubulin protein all from porcine brain were all purchased from Cytoskeleton Inc. 
(Denver, Colorado, US), as were general tubulin buffer (80mM Na-PIPES, pH 6.9, 1mM MgCl2, 1 
mM EGTA), adenosine triphosphate (ATP),  paclitaxel and glycerol. 
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Exchange of octadecylamine ligand on QDs for EG alkanethiol, HS-(CH2)11-EG4-OH. QDs with 
octadecylamine (ODA) ligands in toluene (5 mg mL-1) were diluted 1:40 in THF and vortexed. 
From a 10 mM stock in ethanol, EG alkanethiol ligand was diluted to 1 mM with 1X phosphate-
buffered saline (PBS; 140 mM NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl and 1.2 mM KH2PO4, pH 7.4) 
and 1 volume of this solution was added to the QDs dropwise, vortexing between additions. 
This was then left to react for 4 h on a rotary mixer at room temperature. Following this 
incubation, 1 volume of chloroform was added to the mixture and vortexed before being left 
to stand for 5 min to allow the chloroform and the aqueous phase to separate. The aqueous 
phase was collected and half a volume of chloroform and half a volume of 1X PBS added. After 
vortexing and allowing to stand for 5 min, the aqueous phase was again collected and half a 
volume of chloroform and half a volume of PBS added for a second time, vortexed and allowed 
to stand for 5 min. This was repeated one further time to give a total of four chloroform 
washes. The aqueous phase was then centrifuged for 7 min at 11,000 g. The supernatant was 
removed and the pellet was resuspended in 1X PBS containing 0.01% (v/v) Tween 20 and 1 
mM EG alkanethiol ligand. The QDs were then incubated overnight at 4°C on a rotary mixer. 
The following day, a slurry of Sephadex G-25 superfine in water was added to a 10 mL column 
until the resin bed was 1 mL. The resin was washed thoroughly with H2O Tween-20 0.01% (v/v) 
before being equilibrated with 0.2 mM EG alkanethiol ligand in H2O Tween-20 0.01% (v/v). QDs 
in PBS, 0.01% (v/v) Tween 20 and 1 mM EG alkanethiol were concentrated to between 10 μL 
and 50 μL using a 10 kDa Nanosep centrifugal filtration unit and then loaded onto the 
Sephadex G-25 column. The column was run in H2O Tween-20 0.01% (v/v) and 100 μL fractions 
were collected and examined under UV illumination to identify those corresponding to the 
excluded volume, which contained QDs. These fractions were pooled together and further 
ligand was added (final concentration 0.2 mM) to the QDs. They were incubated overnight at 
4°C on a rotary mixer before separating excess ligand and QDs using size-exclusion 
chromatography with Sephadex G25 superfine, with 1x PBS as the mobile phase. 
Ion-exchange chromatography. DEAE or CM Sepharose was added to 10 mL columns to give a 
volume of 200 μL resin. The resins were equilibrated with 20 column volumes of 1X PBS and 
then washed with 10 column volumes of water. EG alkanethiol capped QDs were concentrated 
to between 10μL and 50μL using a 10 kDa Nanosep centrifugal filtration unit and were then 
resuspended in water. This was repeated three times successively to remove excess 
electrolytes. The EG alkanethiol capped QDs were then loaded onto the columns and the flow-
through collected as one fraction. The columns were then washed with 50 μL aliquots of water 
to remove unbound QDs and each wash was collected as an individual fraction. If QDs were 
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observed by UV illumination to be bound to the column, 100 μL aliquots of 10 mM sodium 
phosphate buffer (pH 7.4) was used to elute the QDs. The QDs from the through fraction and 
the water washes were pooled for use in later experiments. 
Determination of hydrodynamic radius using Dynamic Light Scattering (DLS). DLS 
measurements were carried out using a Zetasizer Nano ZS (Malvern, UK). The sample was 
analysed three times. 
Measurement of quantum yield. The quantum yield of the EG alkanethiol capped QDs was 
measured in comparison to that of the ODA capped QDs obtained directly from NN Labs, LLC 
(Fayetteville, Arkansas, US). The optical density of the two samples was measured using UV-vis 
spectroscopy and sample concentrations were adjusted so that they were equal. Both samples 
were degassed by purging with nitrogen before the emission spectra between 450 nm and 750 
nm were obtained at room temperature using a Cary Eclipse Varian fluorescence 
spectrophotometer at an excitation wavelength of 400 nm. 
Electrolyte-induced aggregation of EG alkanethiol capped QDs. After chromatography, EG 
alkanethiol capped QDs were concentrated to between 10 μL and 50 μL using a 10 kDa 
Nanosep centrifugal filtration unit and were resuspended in 500 μL 1X PBS. This was repeated 
three times to ensure buffer exchange. After the final centrifugation, QDs were resuspended in 
600 μL 1X PBS. NaCl was added to 100 μL aliquots of these QDs to give final NaCl 
concentrations between 250 mM and 2 M. The absorption spectra between 400 nm and 750 
nm of QDs at each concentration of NaCl were then measured at room temperature using a 
SpectraMax Plus384 spectrometer immediately after and 24 h after NaCl addition. 
Ligand-exchange assay using DTT. DTT powder was dissolved in milliQ H2O to make a 1 M 
stock solution and was stored at 4°C. This stock solution was further diluted to give DTT 
concentrations ranging from 0.05 mM to 500 mM. PBS (33 µL 10X) and 10 µL DTT at different 
concentrations were then added to 57 µL EG alkanethiol capped QDs in a 384 well plate. MilliQ 
H2O was used as a reference. The absorption spectra between 400 nm and 750 nm of QDs at 
each concentration of DTT were measured at room temperature using a SpectraMax Plus 384 
spectrometer immediately after and 48 h after DTT addition. 
Preparation of Tris-nitrilotriacetic acid (Tris-NTA) functionalised EG alkanethiol capped QDs. 
Stock solutions of EG alkanethiol and Tris-NTA terminated EG alkanethiol ligands in ethanol (10 
mM) were mixed to give solutions with different percentages of Tris-NTA terminated EG 
alkanethiol ranging from 0.05% to 0.8% (mol/mol) relative to the EG alkanethiol. QDs were 
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then prepared as above, except that EG alkanethiol ligands were substituted with the 
appropriate EG alkanethiol/Tris-NTA terminated EG alkanethiol ligands in all the relevant 
steps. The Tris-NTA functionalised QDs were then transferred to water using 10 kDa Nanosep 
centrifugal filtration units before NiCl2 (250 mM final concentration) was added for 40 min at 
room temperature on the rotary mixer. Excess NiCl2 was removed by size exclusion 
chromatography with Sephadex G25 and water containing 0.01% (v/v) Tween as the mobile 
phase. The Tris-NTA functionalised QDs were finally concentrated and transferred back to 1X 
PBS using 10 kDa Nanosep centrifugal filtration units. 
Titrating the stoichiometry of functionalisation with Tris-NTA terminated EG alkanethiol 
ligands. A hexahistidine affinity column was produced as described to purify QDs with just one 
Tri-Ni-NTA function (Lévy et al. 2006, Duchesne et al. 2008).  Briefly, Strep-Tactin Sepharose 
resin was washed three times with 1X PBS. A biotinylated peptide biotin-GAAHHHHHH (300 
μM final concentration) was then mixed with the Strep-Tactin Sepharose resin in PBS 
containing 0.01% (v/v) Tween. After an overnight incubation on a rotary mixer at room 
temperature, the resin was loaded into a 10 mL plastic chromatography column and washed 
thoroughly with five column volumes of 1X PBS and two column volumes of water containing 
0.01% (v/v) Tween to remove any unbound peptide. Free biotin binding sites were blocked 
with 1 mM biotin and the resin was then washed with ten column volumes of water containing 
0.01% (v/v) Tween and five column volumes of 1X PBS before use. Peptide functionalised resin 
(histidine resin, 10 μL) was added to 100 μL Tris-NTA functionalised QDs and placed on a rotary 
mixer for 2 h to 4 h at room temperature. After this incubation, the peptide functionalised 
resin was allowed to settle and the absorption data at 600 nm of the QDs in the supernatant 
was measured so that the concentration of QDs that were not bound to the resin could be 
calculated. When only 10% of the QDs were bound to the histidine resin, these would contain 
just a single Tris-NTA terminated EG alkanethiol (Lévy et al. 2006). 
Conjugation of hexahistidine-tagged FGF2 to Tris-NTA functionalised QDs. QDs 
monofunctionalised with Tris-NTA EG alkanethiol were concentrated using a 10 kDa Nanosep 
centrifugal filtration unit and their final concentration was determined using their UV-vis 
absorption at 600 nm and an extinction coefficient of 4.9x105 cm-1 M-1. They were then 
incubated with a 40-fold molar excess of hexahistidine-tagged FGF2 for 4 h at room 
temperature or overnight at 4˚C. FGF2-QDs and free hexahistidine-tagged FGF2 were purified 
from unfunctionalised QDs using heparin agarose in a 10 mL column. Unfunctionalised QDs did 
not bind to the column. FGF2-QDs were eluted from the column with 2 M NaCl along with the 
free hexahistidine-tagged FGF2. FGF2-QDs were separated from free FGF2 by centrifuging at 
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4°C for 60 minutes at 17,000 G, removing the supernatant containing the unbound FGF2 and 
then resuspending the pellet of FGF2-QDs in 1X PBS. This was repeated five times to ensure 
that all of the unbound FGF2 had been removed. 
Preparation of streptavidin functionalised QDs. Stock solutions of EG alkanethiol and carboxyl 
terminated EG alkanethiol ligands in ethanol (10 mM) were mixed at a ratio of 9:1 (mole: 
mole). QDs were then prepared as above, except that EG alkanethiol ligands were substituted 
with the EG alkanethiol/carboxyl terminated EG alkanethiol ligands (9:1 mole: mole) in all the 
relevant steps. Once the QDs had been separated from the excess ligand by size-exclusion 
chromatography using Sephadex G25, Streptavidin was then conjugated to the COOH on the 
QD via an EDC condensation reaction to give streptavidin functionalised QDs. Carboxyl 
functionalised QDs (50 µL at 1.5 µM) were made up to 80 µL with 10 mM borate buffered 
saline (10 mM sodium tetraborate, 150 mM NaCl pH, 7.4) before 19.2 µL Streptavidin (10 mg 
mL-1 in 10 mM borate buffered saline, pH 7.4) was added. Five µL EDC (10 mg mL-1 in deionised 
water) was then added to this and the reaction mixture was stirred for two hours and then 
filtered through a 0.2 µm polyethersulfone (PES) syringe. The QDs were then placed in a 100 
kDa Nanosep centrifugal filtration unit and were transferred to 50 mM borate buffered saline 
(50mM sodium tetraborate, 150 mM NaCl, pH 8.3). They were filtered again using a 0.2 µm 
PES syringe before being stored at 4°C. 
Cell culture. Rat mammary (Rama) 27 fibroblasts were cultured, as described (Rudland et al. 
1984), to 70% confluence on Iwaki dishes in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 10% (v/v) fetal calf serum (FCS), 2.5 mM L-glutamine, 50 ng mL-1 insulin, 50 ng mL-1 
hydrocortisone and 50 U mL-1 each of penicillin and streptomycin at 37°C in a humidified 
atmosphere and 10% (v/v) CO2. 
DNA synthesis assay. The stimulation of DNA synthesis was measured as described (Rudland 
et al. 1984). Briefly, Rama 27 cells seeded at 20,000 cells in 24 well plates were allowed to 
attach overnight and then stepped down into serum-free medium (DMEM supplemented with 
250 µg mL-1 bovine serum albumin (BSA) for 30 h. FGF2, FGF2-QDs or EG alkanethiol QDs were 
then added for 18 h after 3H-thymidine (ICN, Basingstoke, UK) was added for 1 h. A control was 
carried out for each 24 well plate, where the cells were incubated with only 250 µg mL-1 BSA 
with no FGF2 or QDs added. DNA was precipitated using 5% (w/v) trichloroacetic acid and the 
incorporation of 3H-thymidine into cellular DNA was quantified by liquid scintillation counting. 
The concentration of FGF2 was quantified using its UV-vis absorption at 280 nm and an 
extinction coefficient of 1.6x104 cm-1 M-1. The concentration of FGF2-QDs was determined 
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using the UV-vis absorption of the QDs at 600 nm and an extinction coefficient of 4.9x105 cm-1 
M-1. 
Specific FGF2 directed binding of QDs to living cells. Rama 27 grown in  Iwaki dishes were 
stepped down into serum-free medium (DMEM with 250 µg mL-1 BSA) for 4 h. After 4 h, fresh 
step down medium was added with EG alkanethiol capped QDs, Tris-NTA functionalised QDs or 
FGF2-QDs (all 10 nM final concentration). After 15 min, the cells were washed three times with 
1X PBS and then were imaged using a Zeiss Laser Scanning Microscope 710 confocal 
microscope with an environmentally controlled stage (humidified atmosphere, 10% CO2, 37˚C). 
A random field that contained cells was taken for observation. Images of the QDs were 
obtained by scanning confocal microscopy (excitation laser wavelength 561 nm, fluorescence 
filter 575-630 nm) and the cells were imaged via differential interference contrast (DIC) 
microscopy. 
Single molecule imaging of QDs on living cells. Glass coverslips (12 mm diameter) were 
washed in ethanol in advance before being placed into the wells of a 24 well plate. Rama 27 
fibroblasts were then seeded and allowed to attach overnight. At 70% confluence, they were 
placed in step-down medium. After 4 h, the step down medium was aspirated and Ringer 
buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2 and 11 mM 
glucose) supplemented with 10 mg mL-1 BSA was added for 10 min. Tris-NTA functionalised 
QDs, FGF2-QDs or EG alkanethiol capped QDs with hexahistidine-tagged FGF2 (all 200 pM final 
concentration) were then added to cells in 1X PBS: Ringer buffer (9:1) supplemented with 10 
mg mL-1 BSA. After incubating for 3 min, the QDs and buffer were aspirated from the 
coverslips. The coverslips were washed three times with Ringer buffer supplemented with 10 
mg mL-1 BSA. Coverslips were mounted into a custom made holder and cell images were 
acquired in Ringer buffer with BSA (10 mg mL-1) at 31°C using an Olympus IX71 inverted 
microscope with a 60X objective (NA 1.42; Olympus, Tokyo, Japan) using an excitation 
wavelength of 455 nm and fluorescence filter of 605 nm (Omega Optical, Brattleboro, VT, 
USA). The movement of FGF2-QDs was recorded in real time over 1600 frames (frame rate 40 
ms) with an ImagEM EMCCD camera (Hamamatsu Photonics, Massy, France) and MetaView 
software (Meta Imaging 7.7). 
Single molecule tracking of FGF2-QDs on living cells. The trajectories of single FGF2-QDs were 
constructed from the real time images obtained using the Olympus IX71 inverted microscope, 
as previously described (Bonneau et al. 2005).  
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Matlab R2011a was used to analyse the diffusion of the FGF2-QDs on the Rama 27 cells as 
described in Duchesne et al. 2012. To summarise, trajectories were divided into subtrajectories 
containing s number of consecutive frames and the X and Y positions of FGF2-QDs were used 
calculate the net displacement (Pj) and distance travelled (Qj) for each subtrajectory.  
 
The above equation gives the displacement, which is the shortest distance between the first 
and the last point in each subtrajectory. 
 
The above equation gives the distance along the actual path between the first and the last 
point in each subtrajectory. 
A scatter plot was then constructed showing the displacement vs. distance travelled for each 
subtrajectory. Obvious confined, simple diffusive and directed diffusive behaviors in 
trajectories were used to set boundaries along the displacement axis for each type of diffusion. 
For this experiment, trajectories were divided into subtrajectories containing 12 frames (s=12), 
the equivalent of 0.48 s. 
Origin Pro 8.6 software was used, as described (Duchesne et al. 2012), to construct a graph of 
the average mean squared displacement (MSD) over time (t) for each of type of diffusion 
shown on the scatter plot according to the following expression:  
      
Equation (1) 
The following equations (Saxton & Jacobson 1997) were then used to calculate the diffusion 
coefficients (D):
 
     (Simple diffusion)        Equation (2) 
    (Directed motion)      Equation (3) 
For confined diffusion, the confinement domain size was defined using the following equation:
             Equation (4) 
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In equation (3),  is the velocity. In equation (4), dconf is the diameter of confinement as 
defined by the asymptote of the curve and Dins is the instantaneous diffusion coefficient which 
is defined by the slope of the curve at the origin and shows the diffusion coefficient before 
confinement effects dominate.  
Preparation of Biotin-PEG glass coverslips. Glass coverslips (12 mm diameter) were cleaned by 
sonicating with 10 M KOH for 20 min, then rinsed 10 times with ddH2O before being dried with 
N2 gas and burned briefly in the flame of a propane torch. An aminosilane solution containing 
75 mL methanol, 3.75 mL acetic acid and 1.5 mL N-(2-aminoethyl)-3-
aminopropyltrimethoxysilane was then prepared in a fume cupboard before being added to 
the dry coverslips in a flask. After 10 min, the coverslips were sonicated for 1 min and then left 
for another 10 min before the aminosilane solution was removed and the coverslips washed 2 
times with methanol and 10 times with ddH2O. The coverslips were then removed from the 
flask and dried with N2 gas and placed in a humidity chamber. A 2% (mole: mole) biotinylated 
PEG mixture was prepared by dissolving 44.1 mg mPEG-Succinimidyl Valerate (MW 5,000) and 
0.9 mg mPEG-Biotin (MW 5,000) in 180 µL sodium bicarbonate (100 mM). The PEG mixture 
was then added to the centre of the coverslips and spread with a pipette tip before another 
coverslip was sandwiched on top. The humidity chamber was then closed and coverslips left 
for 3 h at room temperature before they were taken apart. Biotin-PEG coverslips were then 
rinsed with ddH2O and dried with N2 and stored face up at -20°C. 
Labelling kinesin motor proteins in an in vitro model. Neutravidin (1 mg mL-1 final in dynein 
motility buffer, DmB buffer: 30mM HEPES, 50mM potassium acetate, 2mM magnesium 
acetate, 1mM EGTA, pH 7.2) was added to a biotin-PEG glass coverslip for 5 min. Coverslips 
were then rinsed with DmB buffer and then fluorescently labelled biotinylated microtubules 
were added. These microtubules had been previously prepared by mixing native tubulin with 
biotinylated tubulin (5%) and HiLyte 488 dye (5%) in the ratio 100:12.5:1 (v:v:v) in general 
tubulin buffer (80mM Na-PIPES, pH 6.9, 1mM MgCl2, 1 mM EGTA supplemented with 1mM 
ATP and 5% (v/v) glycerol) and allowing them to polymerise as described (Hoffman 2012). Any 
remaining biotin-binding sites in neutravidin were blocked by saturating the coverslip with 100 
µM biotin. Streptavidin functionalised QDs were conjugated to biotinylated truncated kinesin 
(432 kinesin amino-acids + biotin carrier sequence + his tag) (Hoffman 2012) by incubating 
together for 30 min and then saturating the remaining active streptavidin sites on the QDs 
with biotin. The kinesin functionalised QDs were then added to the microtubules on the glass 
coverslip with ATP (400 nM final concentration) and imaged by Fluorescence Imaging with One 
Nanometer Accuracy (FIONA) (Yildiz et al. 2003, Hoffman et al. 2011). 
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Results 
 
 
 
 
 
 
 
 
Figure 1. Sephadex G25 size-exclusion chromatography of water soluble EG alkanethiol 
capped QDs. QDs were subjected to Sephadex G25 chromatography after the third incubation 
with EG alkanethiol (see Materials and Methods). Images of the QDs on the column (main 
image) and QDs that eluted from the column in the excluded volume, V0 (inset) were taken 
under UV illumination. 
Ligand-exchange mediated transfer of QDs to aqueous solutions. CdSe/ZnS QDs received 
from the supplier were coated in octadecyl amine (ODA) ligands and were soluble in toluene. 
These QDs are a typical product of synthesis and are obviously not suitable for biological 
applications, since they are not soluble in aqueous solutions. A new ligand-exchange protocol 
was developed to remove the ODA ligands and recoat the QDs in ethylene glycol (EG) 
alkanethiol ligands with the aims of achieving good colloidal stability in water and resistance to 
non-specific binding in biological systems. Alkanethiol ligands were chosen, because they have 
been particularly effective in producing robust self-assembled monolayers on noble metal 
nanoparticles (Brust et al. 1994, Shimizu et al. 2003). A number of steps in this protocol (see 
Materials and Methods) need to be highlighted, as they were found to influence strongly the 
quality of the QD ligand shell. 
THF was a good intermediate water miscible solvent, which allowed the QDs passivated with 
ODA, any free ODA ligand and the EG alkanethiol ligand to remain in solution. The presence of 
electrolytes (as phosphate buffered saline [PBS]) in the volume of EG alkanethiol ligands added 
to the QDs was essential to ensure that the QDs produced in this step had a ligand shell 
sufficiently robust for the later steps. The chloroform extraction and subsequent centrifugation 
removed the organic solvents and excess ODA ligand. Without these steps, the EG alkanethiol 
ligand shell did not form effectively and included ODA. The second incubation of the QDs with 
 34 
EG alkanethiol ligand in PBS enabled full self-assembly of a monolayer of ligand on the QDs. 
However, perhaps due to presence of some outgoing ODA ligands, the ligand shell was not yet 
sufficiently robust yet to allow gel filtration in the absence of EG alkanethiol ligand in the 
mobile phase. Thus, in the first gel filtration step, EG alkanethiol ligands were present in the 
mobile phase, which ensured that the QDs eluted in the void volume. In this way, the QDs 
were effectively separated from the outgoing ODA ligands. Consequently, the third incubation 
with the EG alkanethiol ligand achieved maximal ligand-exchange and so a reasonably defect-
free ligand shell.  
To arrive at this optimal protocol, Sephadex G25 superfine, DEAE Sepharose and CM 
Sepharose chromatography were used to identify the most stable QDs. The rationale was that, 
as for gold nanoparticles, stability against electrolyte-induced aggregation is not as good a 
predictor of the stability of nanoparticles in biological environments compared to the absence 
of interaction of nanoparticles with the functional groups in such chromatography resins 
(Duchesne et al. 2008). This is because these different chromatography resins mimic to an 
extent the functional groups found on biomolecules (alcohols, amines, carboxyls) and so can 
indicate whether the QDs would interact non-specifically with biomolecules. Sephadex G25 is 
composed of cross-linked dextran, a very simple polysaccharide. Therefore, any binding of the 
EG alkanethiol capped QDs to this resin would indicate that they would also interact non-
specifically with varied and much more complex biomolecules found in the cellular 
microenvironment. DEAE and CM Sepharose are positively and negatively charged resins, 
respectively and so indicate whether the EG alkanethiol capped QDs are likely to interact non-
specifically with charged biomolecules through electrostatic interactions or hydrogen bonding. 
Resistance to non-specific binding is critical in ensuring later on that any biological interactions 
are due to the functional ligands on the QDs and not the QD shell itself. EG alkanethiol capped 
QDs produced by the present protocol passed through G25 chromatography resin (Fig. 1; main 
picture), eluted in the V0 fraction, and remained brightly fluorescent when examined under UV 
illumination (Fig. 1; inset picture). 
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Figure 2. Stability of EG alkanethiol capped QDs upon ion-exchange chromatography. EG 
alkanethiol ligand capped QDs were transferred to water and concentrated and then subjected 
to DEAE anion-exchange and CM cation-exchange chromatography (Materials and Methods). 
Images were acquired under UV illumination of (A) the flow-through fractions (FT) and the 
subsequent wash with water (W1-W5) and (B) of the DEAE and CM resins after elution with 10 
mM sodium phosphate. 
EG alkanethiol capped QDs that eluted at V0 from the G25 column were subjected to DEAE and 
CM ion-exchange chromatography. DEAE Sepharose is a positively charged resin while CM 
Sephadex is a negatively charged resin. The majority of the EG alkanethiol capped QDs 
prepared by the ligand-exchange protocol flowed through the DEAE resin with water (Fig. 1A); 
the remainder were only weakly bound, since they were eluted with  10 mM sodium 
phosphate (Fig. 2B). All the QDs flowed through the CM resin with water (Fig. 2A). This shows 
that the EG alkanethiol capped QDs were neutral in charge, with the remainder being at most 
slightly negatively charged and that none of the QDs were positively charged. Only those QDs 
that passed through G25 and were washed from DEAE and CM resins with water were deemed 
to possess a sufficiently robust ligand shell for subsequent experiments. DLS showed that 
these EG alkanethiol capped QDs had a small hydrodynamic radius of just 5.6 nm (see 
Appendix II Fig. 1).  This indicates that the ligand shell on the QDs was ~0.2 nm thick, such that 
the QDs were well within the size range of naturally occurring proteins. The quantum yield of 
the EG alkanethiol capped QDs was calculated to be 28% and was, therefore, lower than that 
of the raw materials from the supplier, which had a quantum yield of 40% (see Appendix II Fig. 
2). 
Stability of EG alkanethiol capped QDs in the presence of electrolytes. Colloidal stability of 
the EG alkanethiol capped QDs was measured in the presence of different concentrations of 
NaCl. Loss of stability would be demonstrated by the occurrence of aggregation in the QD 
FT     W1    W2    W3    W4     W5 
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sample. The absorbance spectra for aggregated and non-aggregated QDs are significantly 
different, with the spectrum for aggregated QDs becoming much flatter than that for non-
aggregated QDs.  The addition of NaCl (Fig. 3A and 3B) did not significantly alter the spectra of 
the QDs, even at 2 M NaCl after 24 h (Fig. 3B). Thus, the QDs do not aggregate in the presence 
of electrolytes. 
 
 
Figure 3. Stability of EG alkanethiol capped QDs in the presence of electrolytes. Following 
size-exclusion and ion-exchange chromatography, EG alkanethiol capped QDs were 
concentrated with 10 kDa Nanosep centrifugal filtration units and resuspended in PBS. 
Absorbance spectra were obtained immediately after addition of NaCl to different final 
concentrations (A) and after 24 h incubation (B). 
Resistance to ligand-exchange with DTT. The integrity of the EG alkanethiol ligand shell was 
tested by incubating EG alkanethiol capped QDs with DTT, a small uncharged dithiol, which has 
previously been shown to provide an good measure of the resistance of SAMs on gold 
nanoparticles to ligand-exchange (Chen et al. 2012). Since DTT is a poor ligand in terms of 
colloidal stability in the presence of electrolytes, ligand exchange would be characterised in 
this assay by QD aggregation. Spectra obtained after addition of DTT (Fig. 4A and 4B) to the EG 
alkanethiol capped QDs in the presence of 0.45 M electrolytes showed that there was no 
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significant difference at 50 mM DTT after 48 h (Fig. 4B). Therefore, the incoming DTT 
molecules are unable to replace substantial numbers of the EG alkanethiol ligands from the 
surface of the QDs and that the ligand shell remains sufficiently intact under these conditions 
to withstand electrolyte-induced aggregation. 
 
 
Figure 4. Resistance to ligand-exchange with DTT. EG alkanethiol capped QDs were incubated 
with DTT in the presence of 0.45 M electrolytes (Materials and Methods). Absorbance spectra 
were obtained immediately after (A) and 48 h after (B) addition of DTT at the indicated final 
concentrations.  
Functionalisation of EG alkanethiol capped QDs with Tris-NTA. EG alkanethiol capped QDs 
were functionalised by simply including functionalised ligand (in this instance, Tris-NTA 
terminated EG alkanethiol) with capping ligand at a particular molar percentage.  QDs 
prepared with 0.05% (mol/mol) to 0.8% (mol/mol) Tris-NTA terminated EG alkanethiol were all 
brightly fluorescent and eluted in V0 upon G25 size-exclusion chromatography. 
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Figure 5. Functionalisation of EG alkanethiol capped QDs with Tris-NTA and quantification of 
the number of functional ligands incorporated into the ligand shell.  After G25 size-exclusion 
chromatography, 100 μL QDs was incubated with 10 μL of histidine resin for 2 h at room 
temperature on a rotary mixer. After 2 h, the microtubes were removed from the rotary mixer 
and left for 5 min for the histidine resin to settle. (A) Pictures under UV illumination of the 
microtubes containing the QDs bound to the histidine resin. To quantify the amount of binding 
to the histidine resin, the absorbance of the QDs at 450 nm was measured using a 
spectrometer before and after incubation with the histidine resin to calculate the percentage 
of QDs bound to the histidine resin for each different Tris-NTA percentage (B). 
 
Only those QDs that had incorporated at least one Tris-NTA terminated EG alkanethiol ligand 
would bind to the histidine affinity resin. The higher the percentage of Tris-NTA EG alkanethiol 
ligand used, the more fluorescent the histidine resin pellet was (Fig. 5A), suggesting that more 
QDs had bound to the resin in these circumstances. These results were quantified using 
absorption data for the QDs, which allowed the number of QDs remaining in the supernatant 
to be calculated as a percentage of the number of QDs in the starting solution and, therefore, 
also gave the percentage of QDs that had bound to the histidine resin (Lévy et al. 2006, 
Duchesne et al. 2008). As the percentage of Tris-NTA used to prepare the QDs increased, the 
percentage of QDs bound to the histidine resin also increased (Fig 5B), showing that there was 
0.05%    0.1%     0.2%      0.4%      0.8% 
B 
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a direct relationship between the concentration of Tris-NTA EG alkanethiol ligand used in the 
preparation of the QDs and the number of QDs that had incorporated the Tris-NTA EG 
alkanethiol ligand, in accordance with previous work on gold nanoparticles (Lévy et al. 2006, 
Duchesne et al. 2008).  When 10% of the QDs bound to the resin, corresponding to ~0.05 mole 
% Tris-NTA EG alkanethiol, the QDs would contain just one Tris-NTA EG alkanethiol ligand (Lévy 
et al. 2006, Duchesne et al. 2008). 
 
Conjugation of Tris-NTA functionalised QDs to FGF2. Hexahistidine-tagged fibroblast growth 
factor-2 (FGF2; Duchesne et al. 2008) was added to nickel loaded Tris-NTA functionalised EG 
alkanethiol capped QDs. Those QDs with Tris-NTA EG alkanethiol ligand were expected to bind 
to the hexahistidine-tagged FGF2. QDs were added to a heparin agarose column and those 
that were functionalised with FGF2 bound to the resin (Fig. 6A), shown by the fluorescence 
detected on the resin after it was washed. Two M NaCl eluted the FGF2-QDs, shown by the 
strong fluorescence of the eluate (Fig. 6B and 6C), which demonstrated that the FGF2-QDs 
retained the heparin binding properties of the native FGF2 (Ori et al. 2009). The FGF2-QDs 
retained their colloidal stability for days (Fig. 6C). 
 
             A            B        C 
              
 
 
 
 
 
 
 
Figure 6. Purification of FGF functionalised EG alkanethiol capped QDs by heparin affinity 
chromatography. QDs were added to columns containing heparin agarose resin and unbound 
QDs were washed from the resin using water. Bound QDs were eluted using 2M NaCl and were 
collected as fractions before being transferred to PBS (Materials and Methods). Images were 
obtained under UV illumination of (A) heparin agarose resin after loading the QDs and washing 
the column with water; the intense fluorescence represents FGF2-QDs bound to the resin, (B) 
the heparin agarose after elution of the bound QDs with 2M NaCl and (C) the FGF-
functionalised QDs in 1X PBS two days after elution from the column with 2M NaCl (C). 
 
Stimulation of DNA synthesis in Rama 27 fibroblasts by FGF2-QDs. The QDs used here contain 
elements toxic to cells. A stable ligand shell should prevent leaching of these materials into 
cells. To test whether the QDs were toxic to cells, the growth-stimulatory activity of FGF2 was 
used as an assay; this would also to determine whether conjugation of the QDs affected the 
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biological activity of the FGF2. FGF2 maximally stimulated DNA synthesis in Rama 27 
fibroblasts at 0.3 ng mL-1 (Fig. 7), in agreement with previously published results (Zhu et al. 
2010). Co-incubation of FGF2 with QDs did not affect the dose response.  Moreover, QDs 
monofunctionalised with FGF2 (FGF2-QDs) also stimulated DNA synthesis to the same extent 
as FGF2 alone (Fig. 7). On the other hand, unfunctionalised EG alkanethiol capped QDs 
produced no significant response at any concentration when compared with the negative 
control. Since the QDs are in contact with the cells for 18 h in this assay, the results 
demonstrate that the ligand shell ensures that the QDs are not toxic and that conjugated 
protein retains its native biological activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Stimulation of DNA synthesis by FGF2-QDs. Quiescent Rama 27 fibroblasts were 
stimulated with FGF2 or FGF2-QDs and after 18 h the incorporation of 3H-thymidine into the 
cell DNA was measured. Controls were performed for each condition, where cells were 
incubated with only 250 µg mL-1 BSA with no FGF2 or QDs added (0 ng mL-1 on the graph). 
Results are the mean ± SD of triplicates. One of three experiments is shown.  
 
Specific binding of FGF2-QDs to living Rama 27 fibroblasts. When EG alkanethiol capped QDs 
were added to Rama 27 cells for 15 min and the cells washed, there was no detectable 
fluorescence (Fig. 8A). A similar result was obtained when Tris-NTA functionalised QDs were 
added to the Rama 27 fibroblasts (Fig. 8B). These results demonstrate that the QDs do not bind 
at detectable levels to Rama 27 fibroblasts or the bare culture dish. In contrast, when the 
FGF2-QDs, purified on a column of heparin agarose, were added to the cells, an intense cell 
associated fluorescence was observed (Figs 8C to 8E). This shows that FGF2 is enabling the 
specific binding of the FGF2-QDs to the cells and that the QD ligand shell is effective at 
preventing non-specific binding. 
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Figure 8. Interaction of FGF2-QDs with Rama 27 fibroblasts. Rama 27 fibroblasts were 
cultured in Iwaki glass bottomed dishes until they were 80% confluent. The medium was then 
exchanged for step-down medium and QDs were added for 15 min, after which the cells were 
washed to remove unbound QDs and the medium was replaced. Images were acquired 
immediately after the medium was changed. All images are the combined fluorescence and 
Differential Interference Contrast (DIC) images, showing the cells and the QDs, respectively. (A) 
Cells after incubation with EG alkanethiol capped QDs (B) cells after incubation with Tris-NTA 
functionalised QDs (C) to (E) cells after incubation with FGF2-QDs. (A), (B), (D), and (E) were all 
acquired at 63 time magnification while (C) was acquired at 32 times magnification. 
 
Single molecule imaging of FGF2-QDs on Rama 27 cells. An important area of application for 
QDs is single molecule imaging. The FGF2-QDs were, therefore, used to measure the 
interaction of FGF2 with the pericellular matrix of the Rama 27 cells. When EG alkanethiol 
capped or Tris-NTA functionalised QDs were incubated cells, no labelling was observed (Fig. 9A 
and 9B). However, when the cells were incubated with FGF2-QDs, fluorescent spots could be 
seen where the QDs were binding to the cells (Fig. 9C). This again demonstrates that the 
binding of the QDs to cells is highly specific and due to their functionalisation with FGF2. 
Furthermore, addition of a heparin-derived dodecasaccharide, dp12, to the cells with the 
FGF2-QDs resulted in loss of the majority of, but not all, of these fluorescent spots from the 
surface of the cells (Fig. 9D). This demonstrates that the FGF2-QDs are primarily bound to 
cellular heparan sulfate co-receptor, rather than engaged in a ternary complex of co-receptor 
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and fibroblast growth factor receptor tyrosine kinases (FGFR). The much higher level of binding 
to heparan sulfate is in accordance with the published quantification of these two complexes 
(~400-fold more heparan sulfate than FGFR; Duchesne et al. 2012). 
 
    A                B 
              
    C                D 
              
Figure 9. Single molecule imaging of FGF2-QDs on Rama 27 cells. Rama 27 fibroblasts were 
cultured on 12mm round glass coverslips in a 24 well plate until they were 60-70% confluent. 
The medium was exchanged for step down medium for 4 h and then Ringer buffer 
supplemented with 10 mg mL-1 BSA for 10 min. Tris-NTA functionalised QDs without FGF2 (A), 
EG alkanethiol capped QDs with FGF2 (B), FGF2-QDs (C) and FGF2-QDs with heparin derived 
dodecasaccharide, dp12 (D) were then added to the cells in 1X PBS: Ringer buffer (9:1) 
supplemented with 10 mg mL-1 BSA for 3 minutes. The cells were washed 3 times with Ringer 
buffer supplemented with 10 mg mL-1 BSA and were then imaged in a custom made holder 
using a modified Olympus IX71 inverted microscope at 96 times magnification (see Materials 
and Methods). All images were obtained in Ringer buffer supplemented with 10 mg mL-1 BSA. 
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Single molecule tracking of FGF2-QDs on Rama27 cells. The different types of diffusion of 
FGF2-QDs on Rama 27 fibroblasts were defined by plotting a graph of mean squared 
displacement against distance travelled (Fig. 10A). Different boundaries were tested to find 
those most suitable to distinguish the different types of diffusion undergone by the FGF2-QD, 
by observing trajectories with well defined directed and confined diffusive behaviours. Three 
multicoloured trajectories (Figs 10B-D) show trajectories where there is more than one type of 
diffusive behaviour that can be observed at different times, from movement in small spatial 
planes (confined diffusion) to longer, more directed movements (directed diffusion), whereas 
the red trajectory (Fig. 10E) is a FGF2-QD that is immobile or highly confined to one small area 
throughout the whole trajectory. In total, four different types of diffusion were observed for 
FGF2-QDs (Fig. 10A). Group 1 (red) was the highly confined or immobile FGF2-QDs, where the 
movement of the QDs could not be differentiated from the noise of the system. This group was 
defined by controls that were carried out where immobile QDs on a glass coverslip were 
imaged to determine the background noise of the instrument. Group 2 (blue) was confined 
diffusion (displacement lower than 0.15 µm2) that was distinguishable from Group 1 by virtue 
of undergoing movement greater than the noise of the instrument. Group 3 (magenta) was 
simple diffusion (displacement between 0.15 to 0.40 µm2). Group 4 (gold) was directed 
diffusion (displacement above 0.40 µm2), where the FGF2-QDs were moving for a duration of 
time in one specific direction rather than around a small area. 
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Figure 10. Defining the types of diffusion of FGF2-QDs on Rama 27 fibroblasts. The 
trajectories of single FGF2-QDs were constructed from the real time images obtained using the 
Olympus IX71 inverted microscope, as previously described (Bonneau et al. 2005) and analysis 
performed using Matlab scripts (Duchesne et al. 2012). (A) Different types of diffusion were 
observed and the parameters were defined on a graph of mean squared displacement against 
distance travelled for subtrajectories of 12 frames (0.48 s) by looking at trajectories that clearly 
displayed the different types of diffusion, which are displayed in (B-E). The colour code in panel 
A is used in B to define the different types of diffusion in the exemplar tracks. Group 1 
corresponds to immobile or highly confined diffusion, group 2 to confined diffusion, group 3 to 
simple diffusion and group 4 to directed diffusion.   
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The different diffusive behaviours were further defined by comparing the MSD over time for 
the four different types of diffusive motion (Fig. 11A).  The graph shows that over time 
trajectories in the directed diffusion group have a higher level of displacement than the other 
three groups, as would be expected, with trajectories from group 1 and 2 showing the least 
amount of displacement across the surface of the cell over time. As previously reported for 
gold nanoparticles conjugated to FGF2 (Duchesne et al. 2012), FGF2-QDs were confined (group 
1 and 2) for the majority of the time followed by simple diffusion and then directed diffusion, 
which occurred least often (Fig. 11B). The FGF2-QDs were confined for 82.3% of the time, 
undergoing simple diffusion 14.7% of the time and undergoing directed diffusion for only 3% 
of the time. Very similar results were reported by Duchesne et al. (2012) with FGF2-NPs being 
confined for 83% of the time and undergoing simple diffusion 13% of the time on living cells. 
For FGF2-QDs, confinement that was distinguishable from the background (group 2) was the 
most common type of diffusion observed in both time spent undergoing this diffusive motion 
and number of trajectories, and the average duration of these subtrajectories were the 
longest.  The diffusion coefficients that were calculated for each group also correlate nicely 
with the designated diffusion mode for each group. The diffusion coefficient for the directed 
diffusion group was the highest and grew progressively smaller for the more confined groups.  
Four different types of diffusion were observed for FGF2-QDs on R27 cells – immobile/highly 
confined, confined, simple diffusion and directed diffusion. The total time that FGF2-QDs spent 
undergoing confined and simple diffusion and the diffusion coefficients are similar to values 
previously reported using gold nanoparticle labelled FGF-2 (Duchesne et al. 2012). However, 
there were also differences observed between these experiments that use the same cells, but 
different nanoparticle probes and microscopy. FGF2-QDs were most commonly found 
undergoing confined diffusion rather than highly confined as seen for the gold nanoparticles. 
The diffusion coefficients for the confined regimes are also somewhat higher for the QD 
labelled FGF-2 than for gold nanoparticle labelled protein. For group 1 the coefficient is higher 
due to the higher background noise from the instrument. However these differences are 
smaller than the differences between the different modes of diffusion.  Nanoparticle size is 
unlikely be an issue in this instance. Work on the diffusion of membrane proteins in neurone 
cell membranes has shown that protein diffusion coefficients are not markedly affected by 
when probe size is varied from ~500 nm to ~1 nm (Groc et al. 2007, Triller & Choquet 2008).  
The diffusion coefficients for Groups 3 and 4 correspond to an amalgamation of Groups 3-5 in 
Duchesne et al. because in the present work is on living cells only.  Thus, the values of the 
diffusion coefficients for the present Groups 3 and 4 match well with those reported in the 
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previous work with gold nanoparticles. For example, the diffusion coefficient of group 4 is very 
close to the mean for slow and fast directed diffusion of gold nanoparticles in Duchesne et al. 
(2012).  
      A 
  
 
 
 
 
 
 
Figure 11. Calculating the diffusion coefficients for each type of diffusion. A graph of the 
average mean squared displacement (MSD) against time was constructed for trajectories for 
each different type of diffusive behaviour (A). Dynamic parameters were calculated for the 
trajectories for each different type of diffusion (B). N subtraj is the total number of trajectories 
in each group, while % N subtraj is the number as a percentage of the total number of 
subtrajectories from all groups and % time subtraj is the duration of all the subtrajectories in a 
group as a percentage of the duration of all trajectories from all groups. Duration subtraj (s) is 
the average duration of a trajectory in a given group in seconds. The average diffusion 
coefficients (Dav) for group 1 and 2 were calculated using the total duration and MSD of each 
subtrajectory in the group using equation 2 (Materials and Methods). The instantaneous 
diffusion coefficient (Dins) was calculated by fitting the MSD of trajectories in group 2 between 
0 s and 0.2 s using equation 4 (see Materials and Methods). The diffusion coefficients of group 
3 and 4 were calculated by fitting the MSD vs. time curves to equations 2 and 3, respectively 
(Materials and Methods). 
 B N % time % N Duration D (µm2/s) 
  subtraj subtraj subtraj subtraj (s)   
Group 1: immobile/high 
confinement 5499 19.7 23.8 1.15 ± 0.017 0.00058 ± 0.000008 
            
Group 2: confinement 10148 62.6 43.9 1.99 ± 0.031 
0.0038 ± 0.00005 (Dav); 
0.02 ± 0.0025 (Dins) 
           (D
2
conf =  0.013 ± 0.00096) 
Group 3: simple diffusion 5887 14.7 25.5 0.80 ± 0.007 0.04 ± 0.0014 
            
Group 4: directed diffusion 1571 3 6.8 0.62 ± 0.008 0.156 ± 0.012 
           (v = 0.41 ± 0.021 µm/s) 
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Labelling kinesin motor proteins in vitro. To exemplify the versatility of the QDs in terms of 
functionalisation and application, QDs were synthesized with a 10% (mole/mole) COOH-
terminated EG alkanethiol ligands. This allowed EDC-mediated condensation of the QDs to 
streptavidin and then biofunctionalisation with kinesin, a motor protein that binds and moves 
along microtubules (Vale & Milligan 2000). Microtubules polymerised on glass coverslips 
displayed brightly fluorescent spots after incubation with kinesin functionalised QDs (Fig. 12A), 
which demonstrates the kinesin directed binding of the QDs to the microtubules. Furthermore, 
these QDs were observed moving along the microtubules. Two QDs can be seen attached to a 
microtubule, with the lower QD at four different positions on the microtubule (Fig. 12A). The 
movement of the QDs was further analysed, which showed that the QDs were moving along 
the microtubules at a rate of about 30 nm/sec (Fig. 12B) with step sizes of 7.9 ± 4.9 nm (Fig. 
12C). Thus, the kinesin maintained its functionality since its movement closely relates to the 
previously reported value of 8.3 nm for centre-of-mass steps of kinesins along microtubules 
(Yildiz et al. 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
                     A 
 
 
 
 
 
 
 
 
 
 
 
 
     B            C 
Figure 12. Labelling kinesin motor proteins in vitro.  Kinesin functionalised QDs were added to 
glass coverslips coated with fluorescently labelled microtubules (see Materials and Methods). 
(A) Images were obtained of the movement of QDs along the microtubules using FIONA. The 
displacement of QDs over time was examined (B) along with the step sizes of the kinesins 
moving along the microtubules (C). 
 
 
Discussion 
A novel ligand-exchange protocol has been developed that produces EG alkanethiol capped 
QDs from commercially available QDs coated in ODA and soluble in organic solvents, such as 
toluene. The resulting QDs, which are soluble in aqueous solutions, are highly stable, non-toxic 
to cells and are resistant to non-specific binding.  These QDs meet the requirements outlined 
1 2
3
4
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by Rosenthal and colleagues (Rosenthal et al. 2011). Furthermore, they can be coupled to 
proteins for specific targeting to areas of interest on cell membranes and in the cellular 
microenvironment, whilst retaining full native activity of the protein. The EG alkanethiol ligand 
shell is particularly robust and resistant to displacement by reducing agents, which suggests 
that these QDs would also be suitable for cellular imaging, where there is an abundance of 
these types of molecules. The short ligands used in this ligand-exchange protocol produce QDs 
with a small hydrodynamic radius and also allow controlled functionalisation of the QDs.  
The formation of a SAM by ligand-exchange can be a challenge in itself, since it requires the 
removal of sufficient amounts of the initial stabilising ligand from the surface of the QD to 
obtain the desired high density packing of the incoming ligand. Ligand-exchange on CdSe/ZnS 
QDs with thiolated ligands has been thought to be an even greater challenge, producing 
nanoparticles with low stability due to the lack of affinity of the protonated thiol ligand anchor 
for the Zn surface of the QD (Pong et al. 2008) or a poor yield of the water soluble QDs (Yeh et 
al. 2011). Some success has been achieved by using intermediate ligand-exchange steps, using 
non-thiolated ligands for the transfer from organic solvent to aqueous solvent, and then the 
subsequent ligand-exchange with thiolated ligands (Zylstra et al. 2011). One key to its success 
is identifying the right conditions by screening for ligand-exchange using a series of 
increasingly stringent stability tests, as has been carried out here, starting with simple tests 
that mimic the physiological environment before moving on to tests with real world biological 
applications. A second key to success is the use of multiple steps of ligand exchange, to ensure 
the process goes to completion.  
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2.5 Discussion 
A novel ligand-exchange protocol has been developed that can be used to produce stable EG 
alkanethiol  capped QDs that are soluble in physiological solutions from commercially available 
QDs coated in HDA/ TOPO ligands (Lumidot™ QDs) or ODA ligands (NN-labs QDs) and soluble in 
toluene. To arrive at an optimal ligand-exchange protocol, chromatography on Sephadex G25 
superfine, DEAE Sepharose and CM Sepharose was used to identify the most stable QDs. The 
rationale was that, as for gold nanoparticles, stability against electrolyte-induced aggregation 
is not as good a predictor of the stability of nanoparticles in biological environments compared 
to the absence of interaction of nanoparticles with the functional groups in the 
chromatography resins (Duchesne et al. 2008). This is because these different chromatography 
resins mimic to an extent the functional groups found on biomolecules (saccharides, amines, 
carboxyls) and so can indicate whether the QDs would interact non-specifically with 
biomolecules. Sephadex G25 is composed of cross-linked dextran, a very simple polysaccharide 
composed of glucose monomers. Therefore, any binding of the EG alkanethiol capped QDs to 
this resin would indicate that they would also interact non-specifically to varied and much 
more complex biomolecules presenting multiple hydroxyl groups found in the cellular 
environment. DEAE and CM Sepharose are positively and negatively charged resins, 
respectively, which also possess substantial hydrogen-bonding capability.  Interactions with 
these would indicate whether the EG alkanethiol capped QDs are likely to interact non-
specifically with charged biomolecules through electrostatic interactions or hydrogen bonding; 
both types of bonding occur pervasively between biomolecules. Resistance to non-specific 
binding is critical in ensuring later on that any engineered biological interactions of the QDs are 
due to the functional ligands on the QDs and not to the QDs shell itself.  The importance of 
developing ligand shells for nanoparticles such as QDs cannot be overstressed.  As recently 
reviewed (Rosenthal et al. 2011) most current nanomaterials exhibit considerable non-specific 
binding.  The disciplinary gap between chemistry and biology is perhaps responsible in part for 
the current prevalence of substandard probes based on nanomaterials in the literature, a small 
fraction of which are documented in this review. 
A number of steps in the ligand-exchange protocol were found to strongly influence the quality 
of the QD ligand shell. THF was found to be a good intermediate solvent for use in the ligand-
exchange protocol. Chloroform, on the other hand, was a less successful intermediate solvent. 
This is likely due to THF being a water miscible solvent, thus allowing the QDs passivated with 
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the HDA/TOPO, any excess HDA/TOPO ligand and the EG alkanethiol ligand to remain in 
solution. 
The presence of electrolytes (as 1 X PBS) in the volume of EG alkanethiol ligands added to the 
QDs was essential to ensure that the QDs produced in this step had a ligand shell sufficiently 
robust for the subsequent steps. When the EG alkanethiol QDs were produced using water as 
the aqueous phase with no electrolytes present, the ligand shell was less robust, shown by the 
fact that fewer QDs were soluble in aqueous solution after the ligand-exchange protocol was 
carried out. Surprisingly, the use of 10 X PBS as the aqueous phase also produced less stable 
QDs, perhaps because the QDs produced early on in the ligand-exchange protocol were not 
robust enough to remain stable in the presence of such a high concentration of electrolytes. 
The chloroform extraction and subsequent centrifugation removed the organic solvents and 
excess HDA/TOPO or ODA ligands. Three chloroform washes were sufficient to remove 
HDA/TOPO ligands for the Lumidot™ QDs to pass through all three chromatography resins 
used as stability tests. With fewer chloroform washes, QDs bound to Sepharose DEAE resin, 
meaning that the QDs had a net negative charge. This suggests that there may have been 
residual TOPO ligands present on the surface of the QDs or that the ligands had flipped round 
to expose the phosphine oxide group to the aqueous environment rather than the 
hydrophobic alkyl chain, as is the case when the QDs are in toluene, or that other negatively 
charged ligands that were unspecified by the supplier were present and hadn’t been washed 
away. For NN-labs QDs, on the other hand, four chloroform washes and a longer incubation 
with the first load of EG alkanethiol ligand were required to remove sufficient ligands for the 
QDs to pass through the three chromatography resins. Interestingly, even though these QDs 
were only supposed to be coated with ODA ligands upon receipt, the extra wash was actually 
required to allow the EG alkanethiol capped QDs to pass through the positively charged DEAE 
resin, as they were able to pass through the other resins with only three washes, as was 
carried out with the Lumidot™ QDs. If ODA was the only ligand on the surface before ligand-
exchange, any residual ligand would flip to present an amine group to the aqueous 
environment and so binding to CM would be more likely. Personal communication with NN-
Labs, however, revealed that the QDs also had some oleic acid on the surface too, which would 
explain the attachment to the positively charged DEAE resin. The difference is probably due to 
the lack of TOPO ligands on the NN-labs QDs. TOPO ligands have three alkyl chains and are 
bulkier than alkyl amine groups, which have only one. This would affect the packing of the 
ligand shell, meaning that the Lumidot™ ligand shell would be less densely packed than that of 
the NN-labs and, therefore, the HDA/TOPO outgoing ligands would be more easily removed 
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with less chloroform washes than the ODA ligands alone. Furthermore, the incoming EG 
alkanethiol ligand would have more outgoing ligand to compete with for space on the surface 
of the QD to which it could attach.  This work highlights the importance of optimising the 
ligand exchange conditions for any new QDs (or batch of QDs), rather than following the 
current protocols exactly. 
It might come as a surprise that washing the Lumidot™ QDs with toluene before the ligand-
exchange protocol was carried out resulted in QDs that were not subsequently stable in water, 
due to that fact that the QDs are dissolved in toluene when they are received from the 
supplier; it was expected that the removal of some of the excess ligands before the ligand-
exchange protocol was carried out would result in better quality hydrophilic QDs. It might be 
that the early removal of excess HDA and TOPO ligands causes the QDs to destabilise in the 
toluene and that this cannot later be rescued by the addition of EG alkanethiol when 
transferring the QDs to the aqueous phase in the ligand-exchange protocol. On the other hand, 
the instability might be due to the increased volume of toluene in the ligand-exchange 
protocol. When toluene washes were not carried out before ligand-exchange, the QDs were 
dissolved in only 10 μL of toluene. However, this volume rose to 50 μL when the QDs were 
washed with toluene, thus changing the ratio of toluene and THF. The problem here is that it 
was not possible to reduce the volume of toluene below 50 μL in the Nanosep tube.  This was 
due to the extremely low density of toluene, the g force limitations of the Nanosep centrifugal 
devices (maximum 9,000 g) and the limited time the toluene could be in contact with the 
Nanosep centrifugal unit Omega membrane filter before it would cause it to swell too much 
for liquid to pass through the pores. Reducing the toluene from 500 μL to 50 μL in the Nanosep 
tube already took over 2 hours. 
The Mix-matrix has previously been demonstrated to be an excellent ligand shell to prepare 
gold nanoparticles for use in physiological environments (Duchesne et al. 2008; Chen et al. 
2012).  However, attempts to cap Lumidot™ QDs with Mix-matrix ligands were unsuccessful, 
with Mix-matrix capped QDs failing to go through the Sephadex G25 chromatography resin. 
Using Mix-matrix capped QDs would have some advantages over the use of EG alkanethiol 
capped QDs in terms of functionalisation. The Tris-NTA EG alkanethiol functional ligands are 
not currently commercially available and are difficult to synthesise. Single NTA EG alkanethiol 
has recently become commercially available from Prochimia, but is very expensive and will not 
bind a hexahistidine tag with the same avidity as Tris-NTA. The peptidols in the Mix-matrix 
shell are commercially available and are easy to modify in order to provide functionality. One 
possible explanation for the instability of the Mix-matrix capped QDs is that the peptidol might 
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have a greater affinity for the surface of the QDs than the EG alkanethiol ligand, because 
peptidols are able to anchor to the QD surface via amides of the peptide backbone, and/or the 
amine and thiol group of the terminal cysteine. Thus, when the Mix-matrix ligands are added 
to the QDs in the second ligand incubation, peptidols could be displacing the EG alkanethiol 
from the surface of the QDs and so destabilise them causing their aggregation. This same 
instability was observed when gold nanoparticles were capped only with the peptidol without 
the EG alkanethiol ligand, because the peptidol alone is insufficient to cause the repulsion 
between nanoparticles required to prevent aggregation (Duchesne et al. 2008). When Mix-
matrix ligands are used to coat gold nanoparticles, this type of competition between the 
peptidol and EG alkanethiol is less likely due to the fact that both of these interact with the 
gold surface only via the thiol group, since the amides have a substantial lower affinity for 
gold. 
After the optimisation of the ligand exchange protocol had been completed, a new batch of 
Lumidot™ QDs was obtained from the supplier, on which ligand-exchange with EG alkanethiol 
ligand could not be successfully carried out. This batch of QDs exhibited a normal absorption 
spectrum, but had two peaks in the emission spectrum, one at 600 nm, as expected, and an 
extra one at 700 nm. One of the well noted qualities of using QDs in optical imaging is their 
size tunable fluorescence (Bruchez et al. 1998). Therefore, these two emission peaks indicated 
a difference in the QDs structure and also explained the browner than usual colour of the QD 
solution. The morphology of the QDs was examined by TEM and they were found to be rod 
shaped rather than the usual spheroid shape. Therefore, the QDs were asymmetric and the 
long axis of the QDs was probably the reason for the extra red-shifted peak at 700 nm.  
The rod shape of the QDs may be responsible for their instability after ligand-exchange. Recent 
work in the lab has demonstrated the difficulty in stabilising gold nanorods with Mix-matrix 
ligands, a ligand shell that was shown to confer excellent stability to gold nanoparticles 
(personal communication with Breviglieri 2010). Therefore, it would seem reasonable that a 
ligand shell previously used to stabilise spherical QDs would not have the same quality with 
‘quantum rods’. 
The search for a new supplier of QDs to use in the ligand-exchange protocol with EG 
alkanethiol ligand gave some insight into the interactions of alkyl amine and TOPO ligands with 
the surface of CdSe/ZnS QDs. It was initially expected that the most suitable substitute for the 
Lumidot™ QDs would be those from American Elements, as both of these sets of QDs were 
coated in the same hydrophobic stabilising ligands, HDA and TOPO.  This, however, was not 
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the case. Both the American Elements QDs and PlasmaChem QDs that were coated in only 
TOPO ligands were less fluorescent after ligand-exchange than those from Ocean NanoTech 
and NN-Labs and they also showed signs of aggregation at the bottom of the microtube. This 
showed that less of the American Elements and PlasmaChem QDs had undergone sufficient 
ligand-exchange with EG alkanethiol ligand and were soluble in aqueous solutions. In 
comparison, EG alkanethiol capped QDs prepared with Ocean NanoTech and NN-Labs QDs, 
which were both capped with only ODA ligands, showed no such signs of instability and passed 
through Sephadex G25 chromatography in V0. This suggests that EG alkanethiol ligands might 
be able to more easily displace alkyl amine ligands than TOPO ligands, either because the 
TOPO ligands adsorb more strongly that the alkyl amine ligands or because the EG alkanethiol 
ligands are more easily able to access the QD surface through a shell of single alkyl chains of 
HDA and ODA ligands than TOPO ligands. 
It may come as a surprise that the American Elements QDs exhibited such instabilities after 
ligand-exchange, considering that they appeared to be the most similar to the original 
Lumidot™ starting materials. Little is known about the ratios of HDA/TOPO ligands on either of 
the QDs. It could be that there is a higher level of TOPO ligands on the American Elements 
QDs, which bind more strongly to the QD surface and, therefore, are more difficult to displace 
with the EG alkanethiol ligands. On the other hand, it could be that there is a lower level of 
TOPO ligands on the American Elements QDs, thus allowing better packing of the HDA ligands 
on the surface that are more difficult to wash away, leaving less defects on the surface for the 
EG alkanethiol ligands to colonise in the first EG alkanethiol ligand incubation. The ODA that 
coats the Ocean NanoTech and NN-Labs QDs is only two carbons longer than HDA and both 
ligands anchor to the QD surface in the same way, through the amine group. Thus, the ease of 
displacement of these ligands with EG alkanethiol is probably relatively similar and could 
explain why it is possible to stabilise these QDs in the same way as the Lumidot QDs, although 
there is no real explanation as to why NN-Labs QDs seems to undergo ligand exchange that bit 
better than the Ocean NanoTech QDs.  
It is obvious that the composition of the stabilising shell when received from the supplier, both 
in terms of molecular species present and ratios of ligands, is an important determinant in 
whether the QDs are successful or not in the ligand-exchange protocol with EG alkanethiol.  
This is made all the more complicated by the fact that most suppliers are not forthcoming 
about any other components that might be present in the QD solution. The results shown here 
also depict how the shape of the QD might influence whether a QD will work well or not. All of 
this means that it can be difficult to predict which QDs from which suppliers and even from 
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which batch would successfully undergo ligand-exchange with this ligand-exchange protocol.  
Thus, the conditions described here are likely to encompass the optimum protocol for ligand 
exchange, but this must be established empirically. 
Keeping the hydrodynamic radius of QD probes to a minimum has already been discussed and 
is a critical requirement. The DLS results show that hydrodynamic radius of the EG alkanethiol 
capped QDs is 5.6 nm, well within the range of sizes of naturally occurring proteins. The QD 
core is 5.2 nm and so the given hydrodynamic radius corresponds to an increase in size of 0.4 
nm. The maximum length of the EG alkanethiol ligand is 0.385 nm, as calculated from the bond 
lengths and so the maximum hydrodynamic radius of the QDs, if the EG alkanethiol ligands 
were orientated perpendicular to the surface, is 5.97 nm. The fact that the actual measured 
hydrodynamic radius is smaller than the predicated hydrodynamic radius suggests that the EG 
alkanethiol ligands are not surface normal, but are inclined at an angle less than 90°. 
2.6 Conclusions 
A protocol has been developed that allows the assembly of a very robust shell of small EG 
alkanethiol ligands on QDs and some of the parameters influencing the robustness of this 
ligand shell have been explored. This protocol is adaptable to other QDs, because the means to 
assess the success of ligand-exchange has also been developed. The QDs produced in this 
protocol clearly meet the criteria described in Rosenthal et al. (2011), with respect to surface 
modification and functionalisation, small size and lack of non-specific binding. An important 
consideration is whether the ligand-exchange strategy can be adapted to nanomaterials other 
than QDs by making changes to the anchoring moiety of the ligand. If this was the case, then it 
could provide a general solution to a major challenge in Nanobiotechnology, the application of 
nanomaterials to solve real biological problems, by having a well defined ligand shell that can 
be used for many nanomaterial cores. 
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Chapter 3 
Transposing the Ligand Shell onto 
Superparamagnetic Iron Oxide Nanoparticles 
(SPIONs) 
3.1 Overview 
The spotlight has long been on SPIONs for use as in vivo MRI contrast enhancing agents and 
some iron oxide nanomaterials designed for this purpose have already received FDA approval 
(U.S. Food and Drugs Administration ‘Drugs@FDA’ database). However, more recently, the 
development of photothermal microscopy for detection of SPIONs inside cells in vitro (Bogart 
et al. 2012), also allows for the future development of this technique for specific labelling of 
cellular compartments and biomolecules for imaging and biomolecular tracking purposes, in 
addition to whole cell tracking. This chapter considers whether the ligand shell developed for 
the QDs would be suitable for iron oxide nanomaterials simply by changing the foot of the 
ligand so that it can adsorb onto the iron oxide surface. 
3.2 Materials and Methods 
3.2.1 Materials 
Sodium iodide, benzyl bromoacetate, acetone, diethyl ether, sodium hydrogen carbonate, 
acetonitrile, ethyl acetate, magnesium sulphate, di-tert-butyl dicarbonate (Boc2O), 4-
(dimethylamino) pyridine (DMAP), dichloromethane (DCM), petroleum ether, ethanol, 
dimethylformamide (DMF), thionyl chloride, fluorenylmethoxycarbonyl-O-(benzylphospho)-L-
serine (Fmoc-Ser(PO3BzlH)-OH), N,N-diisopropylethylamine (DIEA), piperidine, O-(benzotriazol-
1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), 4-methylmorpholine 
(NMM), trifluoroacetic acid (TFA), ascorbic acid, trisodium citrate dihydrate, ammonium 
acetate and 3-(2-pyridyl)-5,6-di(2-furyl)-1,2,4-triazine-5′,5′′-disulfonic acid disodium salt 
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(ferrozine) were all purchased from Sigma-Aldrich (Dorset, UK) at the highest purity and used 
without further purification. The EG alkanethiol ligand, HS-(CH2)11-EG4-OH, was purchased from 
Prochimia (ProChimia Surfaces Sp. z o.o, Sopot, Poland). Palladium hydroxide (99% purity) was 
purchased from Alfa Aesar (Heysham, Lancashire, UK). Trityl chloride resin (Trt-Cl resin, 100-
200 mesh, 1% (w/v) divinyl benzene (DVB) crosslinking, 1.0-2.0 mmol/g loading) was 
purchased from Iris Biotech (Marktredwitz, Germany). SPIONs (8.5 nm diameter) coated in 
oleic acid and soluble in toluene, prepared as described (Park et al. 2004), were a gift from 
Anita Peacock (Department of Chemistry, University of Liverpool). Nanosep centrifugal 
ultrafiltration devices (10 kDa) were purchased from PALL (PALL Corp., Portsmouth, Hants, UK). 
Sephadex G-25 superfine, diethylaminoethyl (DEAE) Sepharose Fast Flow and carboxymethyl 
(CM) Sepharose Fast Flow were purchased from GE Healthcare (Little Chalfont, Bucks, UK). 
3.2.2 Synthesis of the EG alkane phosphoserine ligand 
The EG alkane phosphoserine ligand for the SPIONs was synthesised using the protocol 
depicted in schemes 3.3.1 and 3.3.2 and detailed below. Where possible, the progress of the 
reaction was monitored by thin layer chromatography (TLC) and reaction products were 
characterised by 1H NMR using a Bruker AMX 400 at 400 MHz.  
3.2.2.1 Synthesis of Benzyl iodoacetate (1) 
 
Sodium iodide (5 mmol) was added to a solution of benzyl bromoacetate (1 mmol) in acetone 
(5 mL/mmol) at room temperature and stirred for 2 h. The reaction mixture was diluted with 
diethyl ether and stirred at room temperature for 20 min before being filtered through celite 
and concentrated in vacuo. The residue was suspended in diethyl ether and filtered through 
celite to give the product as an orange oil, which was used without further purification (94% 
yield).  
1H NMR (400 MHz, CDCl3): 7.39-7.26 (5H, m, 5 x ArH), 5.18 (2H, s, CH2Ph), 3.82 (2H, s, CH2I). 
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3.2.2.2 Synthesis of Benzyl-1-hydroxy-3,6,9,12-tetraoxa-24-thiahexacosan-26-oate (3) 
 
A solution of the EG alkanethiol ligand 2 (1 mmol) and benzyl iodoacetate (1 mmol) in 1 M 
aqueous sodium hydrogen carbonate (2 mL/mmol) and acetonitrile (4 mL/mmol) was stirred at 
room temperature for 3 h. The product was extracted with ethyl acetate (3 x 10 mL) and the 
combined organics were dried over MgSO4 then concentrated in vacuo. The crude product was 
purified using flash column chromatography (SiO2 eluting with ethyl acetate) to give the 
product as a pale yellow oil (90% yield).  
1H NMR (400 MHz, CDCl3): 7.38-7.32 (5H, m, 5 x ArH), 5.17 (2H, s, CH2Ph), 3.74-3.58 (16H, m, 8 
x CH2), 3.45 (2H, t, J 6.9, CH2), 3.26 (2H, s, CH2), 2.66-2.58 (3H, m, CH2 and OH), 1.62-1.25 (18H, 
m, 9 x CH2). 
3.2.2.3 Synthesis of Benzyl-2,2-dimethyl-4-oxo-3,5,8,11,14,17-hexaoxa-29-thiahentriacontan-
31-oate (4) 
 
Boc2O (1.1 mmol) was added to a solution of 3 (1 mmol) and 4-(dimethylamino) pyridine 
(DMAP; 0.1 mmol) in DCM (10 mL/mmol) and the resulting solution was stirred at room 
temperature overnight. The reaction mixture was washed with saturated aqueous NaHCO3 and 
water then dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
flash column chromatography (SiO2 eluting with petroleum ether:ethyl acetate 4:1) to give the 
product as a colourless oil (55% yield).  
1H NMR (400 MHz, CDCl3): 7.31-7.27 (5H, m, 5 x ArH), 5.10 (2H, s, CH2Ph), 4.15-4.12 (2H, m, 
CH2) 3.65-3.49 (14H, m, 7 x CH2), 3.37 (2H, t, J 6.8, CH2), 3.18 (2H, s, CH2), 2.53 (2H, t, J 7.4, 
CH2), 1.58-1.22 (27H, m, 9 x CH2 and 3 x CH3). 
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3.2.2.4 Synthesis of 2,2-Dimethyl-4-oxo-3,5,8,11,14,17-hexaoxa-29-thiahentriacontan-31-oic 
acid (5) 
 
Palladium hydroxide (0.1 mmol) was added to a solution of 4 (1 mmol) in ethanol (20 
mL/mmol). The reaction mixture was evacuated and back-filled with hydrogen three times and 
then stirred under an atmosphere of hydrogen for 4 h. The reaction mixture was filtered 
through a pad of celite and then concentrated in vacuo to give the product as a colourless oil 
(98% yield). 
 1H NMR (400 MHz, CDCl3): 11.46 (1H, brs, OH), 4.18-4.16 (2H, m, CH2) 3.65-3.40 (16H, m, 8 x 
CH2), 3.23 (2H, s, CH2), 2.64 (2H, t, J 7.3, CH2), 1.57-1.22 (27H, m, 9 x CH2 and 3 x CH3). 
3.2.2.5 Pre-activation of Trityl Chloride (Trt-Cl) resin 
The Trt-Cl resin was pre-activated, as described (Harre et al. 1999), by adding thionyl chloride 
1.7% (v/v) in DCM and stirring for an hour at room temperature. The resin was then filtered 
and washed with DMF once and then with DCM three times before being vacuum dried. 
3.2.2.6 Coupling of Fmoc-O-(benzylphospho)-L-serine to Trt-Cl resin (6) 
 
Fmoc-O-(benzylphospho)-L-serine was conjugated to the activated Trt-Cl resin adding the 
Fmoc-serine-phosphate 2 mmol) and N,N-diisopropylethylamine (DIEA) (2 mmol) to the dried 
resin (1 mmol) in DMF (10 mL/mmol) and then stirring at room temperature overnight. The 
resin was filtered and washed sequentially with DMF and diethyl ether then dried under 
vacuum. 
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3.2.2.7 Fmoc deprotection of Fmoc-O-(benzylphospho)-L-serine on Trt-Cl resin (7) 
 
The amine of the Fmoc-O-(benzylphospho)-L-serine was deprotected by adding piperidine 20% 
(v/v) in DMF (10 mL/mmol) to the dried resin (1 mmol). The reaction was stirred at room 
temperature overnight. The resin was then filtered and washed sequentially with DMF and 
then diethyl ether then dried under vacuum. 
3.2.2.8 Coupling of the compound (4) to phosphoserine on Trt-Cl resin (8) 
 
The Boc protected EG ligand 5 was then conjugated to the amine of the phosphoserine. 
Activation of the carboxylic acid of 5 (1 mmol) was performed by adding N,N,N’,N’-
tertamethyluronium hexafluorophosphate (HBTU; 2 mmol) in DMF (5 mL/mmol) followed by 
4-methylmorpholine (NMM; 2 mmol). This mixture was then stirred at room temperature for 
30 min. This was then transferred to second vial containing the resin (0.5 mmol) in DMF (5 
mL/mmol) and the reaction mixture was stirred at room temperature overnight. The resin was 
collected by filtration and washed with DMF then water to remove the urea by-product. The 
resin was then washed sequentially with DMF and then diethyl ether before being vacuum 
dried. 
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3.2.2.9 Acid cleavage of the Trt-Cl resin to prepare the (28S)-28-
((((benzyloxy)(hydroxy)phosphoryl)oxy)methyl)-1-hydroxy-26-oxo-3,6,9,12-tetraoxa-24-thia-
27-azanonacosan-29-oic acid (9) 
 
Cleavage from the resin was achieved using DCM:TFA (10:1) which also removed the Boc 
protecting group yielding 9 in an overall yield of 45%.  
1H NMR (400 MHz, d-6-DMSO): 10.55 (2H, brs, 2 x OH), 7.45-7.38 (5H, m, 5 x ArH), 5.36-5.32 
(2H, m, CH2), 4.44-4.41 (1H, m, 1 of CH2), 3.65-3.40 (22H, m, 10 x CH2, CH and one of CH2), 3.18 
(2H, s, CH2), 2.58 (2H, t, J 7.4, CH2), 1.54-1.22 (18H, m, 9 x CH2). 
3.2.2.10 Synthesis of (S)-1-hydroxy-26-oxo-28-((phosphonooxy)methyl)-3,6,9,12-tetraoxa-24-
thia-27-azanonacosan-29-oic acid (EG alkane phosphoserine) (10) 
 
Palladium hydroxide (0.1 mmol) was added to a solution of 9 (1 mmol) in ethanol (10 
mL/mmol). The reaction mixture was evacuated and back-filled with hydrogen three times and 
then stirred under an atmosphere of hydrogen for 4 h. The reaction mixture was filtered 
through a pad of celite and then concentrated in vacuo to give the product as an off white 
solid (95% yield). 
1H NMR (400 MHz, d-6-DMSO): 11.22 (2H, brs, 2 x OH), 10.99 (1H, brs, OH) 4.48-4.43 (1H, m, 1 
of CH2), 3.63-3.42 (22H, m, 10 x CH2, CH and one of CH2), 3.19 (2H, s, CH2), 2.58-2.55 (2H,m, 
CH2), 1.60-1.23 (18H, m, 9 x CH2). 
 
 
 62 
3.2.3 Exchange of oleic acid ligand on SPIONs for EG alkane phosphoserine 
SPIONs were diluted to 5 mg mL-1 with toluene and 500 µL placed in a 10 kDa Nanosep 
centrifugal filtration unit. They were concentrated to 100 µL by centrifuging at 9000 g at 4°C, 
with the filtration unit being changed if it showed signs of swelling due to long contact with the 
toluene. The SPIONs were then made back up to 500 µL with toluene before being 
concentrated back down to 100 µL. This was repeated a further two times to give four toluene 
washes in total. After the final centrifugation, SPIONs were made up to 500 µL in toluene (5 mg 
mL-1) and were then diluted 1:40 in THF and vortexed for 1 min. From a 10 mM stock in 
ethanol, the EG alkane phosphoserine ligand was diluted to 2 mM with 150 mM NaCl in 
deionised water. One volume of this solution was slowly added to the SPIONs dropwise, 
vortexing well between additions. This was then left to react overnight at 4°C and then for 4 h 
at room temperature the following day. The SPIONs were centrifuged for 7 min at 11,000 g 
and the supernatant removed. The pellet was resuspended in deionised water containing 150 
mM NaCl and 2 mM EG alkane phosphoserine ligand and was incubated for 48 h at 4° on a 
rotary mixer. The SPIONs were then concentrated with a Nanosep centrifugal filtration unit 
and subjected to size-exclusion chromatography with Sephadex G25 superfine, as described 
for QDs (Chapter 2, Section 2.4 Materials and Methods), except with 150 mM NaCl as the 
mobile phase and equilibration of the column with 0.2 mM EG alkane phosphoserine ligand. 
SPIONs eluting in the void volume were reincubated with 0.2 mM EG alkane phosphoserine 
ligand overnight at 4°C on a rotary mixer. The following day, excess ligand was separated from 
the SPIONs using size-exclusion chromatography on Sephadex G25 superfine, with 1x PBS as 
the mobile phase. Tween-20 was then added to the SPIONS eluting in the void volume give a 
0.01% (v/v) final concentration. 
3.2.4 Ion-exchange chromatography  
DEAE or CM Sepharose was added to 10 mL columns to give a volume of 200 μL resin. The 
resins were equilibrated with 20 column volumes of 1X PBS and then washed with 10 column 
volumes of water. SPIONs were concentrated to between 10μL and 50μL using a 10 kDa 
Nanosep centrifugal filtration unit and were then resuspended in water. This was repeated 
three times to remove excess electrolytes. The SPIONs were then loaded onto the columns and 
the flow-through collected as one fraction. The columns were then washed with 50 μL aliquots 
of water to remove unbound SPIONs. Eluted SPIONs were collected as one fraction. 
 63 
3.2.5 Citrate assay 
A citrate assay was carried out, as previously described (Arbab et al. 2005, Lévy et al. 2010, 
Soenen et al. 2010) to determine the stability of the SPIONs when challenged by a small 
chelating agent. SPIONs (1 µg) were incubated with 100 µL sodium citrate tribasic (20 mM in 
PBS) at pH 7.14, 5.5, and 4.5 for up to 9 days at 37°C in separate wells of a 96 well plate. 
Ferrozine reagent (30 µL, 6.5 mM ferrozine, 100 mM ascorbic acid and 1M ammonium acetate 
in deionised water) was then added to each of the wells for 3 h. The absorbance at 595 nm 
was measured using a SpectraMax Plus384 spectrometer. The amount of iron ions in the 
solution was then determined by comparing to a calibration curve produced with different 
dilutions of an iron standard containing up to 1 µg of iron. 
3.3 Results 
3.3.1 Synthesis of the EG alkane phosphoserine ligand.  
The EG alkanethiol ligand was Boc protected at the OH terminus and carboxymethylated at the 
thiol terminus to give ligand 5 (Fig. 3.1). This was then reacted with the deprotected amine on 
the phosphoserine that had been immobilised on the Trt-Cl resin. The phosphoserine was 
cleaved from the resin with TFA and the benzene group hydrogenated to give 10 (Fig. 3.2). The 
overall yield of the final ligand, EG alkane phosphoserine (10) was quite low at 21%, due to low 
yields of products 4 and 8.  
 
 
Figure 3.1 Schematic of the synthesis of 2,2-Dimethyl-4-oxo-3,5,8,11,14,17-hexaoxa-29-
thiahentriacontan-31-oic acid (5) 
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Figure 3.2 Schematic of the synthesis of (S)-1-hydroxy-26-oxo-28-((phosphonooxy)methyl)-
3,6,9,12-tetraoxa-24-thia-27-azanonacosan-29-oic acid (EG alkane phosphoserine) (10) ligand 
by solid-phase synthesis. 
 
3.3.2 Ligand-exchange mediated transfer of SPIONs to aqueous solutions.  
Upon receipt, the SPIONs were coated in oleic acid ligands and were soluble in toluene (Fig. 
3.3A). As with the QDs, for these SPIONs to be suitable for biological applications, they first 
have to undergo ligand exchange to render them soluble in aqueous solutions (Fig. 3.3B).  
A modified version of the QD ligand-exchange protocol was developed for the SPIONs. Some of 
the protocol remains very similar in that they both require THF to act as an intermediate 
solvent for the ligand-exchange reaction to take place, multiple loadings of the incoming ligand 
and a ligand-exchange step using Sephadex G25 chromatography equilibrated with the 
incoming ligand. However, some changes were made. No chloroform washes were performed 
during the SPION ligand-exchange protocol, as it was found that performing washes of the 
SPIONs using toluene before any EG alkane phosphoserine ligand was added was sufficient to 
remove enough of the outgoing ligand to make efficient ligand exchange possible without 
destabilising the nanoparticles. When the EG alkane phosphoserine ligand was added, it was 
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added in 150 mM NaCl rather than PBS. The NaCl provided the electrolytes required to drive 
the packing of the monolayer, but without the phosphate ions present in PBS, which could 
have competed with the incoming ligand and prevented the formation of a SAM sufficiently 
robust to impart good colloidal stability. Furthermore, longer incubation times and higher 
concentrations of incoming ligand were required for ligand-exchange to occur on the SPIONs 
than was necessary for the QDs. which suggests that the interactions between the SPION 
surface and the carboxyl group of the oleic acid may be more stable than the interactions 
between the ZnS shell of the QDs and the amine groups of the ODA. 
                                            A                  B   
 
 
 
 
 
Figure 3.3 Exchange of oleic acid ligand on SPIONs for EG alkane phosphoserine.  SPIONs 
coated in oleic acid and soluble in toluene (A) underwent ligand-exchange (Section 3.2.3) to 
produce EG alkane phosphoserine capped SPIONs that were soluble in aqueous solutions (B). 
 
As with the QDs, the stability of the water soluble SPIONs against non-specific interactions was 
tested with biomimetic chromatography resins, Sephadex G25 superfine, DEAE Sepharose and 
CM Sepharose. Resistance to non-specific binding is, perhaps, even more critical for SPIONs, 
which have the potential to be used for in vivo imaging, than it is for QDs used in vitro imaging 
of cells and biomolecules. A full understanding of both non-specific interactions of the ligand 
shell and specific targeting by functional ligands when nanoparticles are transplanted in vivo 
are almost certainly a prerequisite of nanoparticles gaining regulatory approval. 
EG alkane phosphoserine capped SPIONs passed through the G25 chromatography resin (Fig. 
3.4A) and were eluted in the excluded volume (Fig. 3.4B). 
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Figure 3.4 Sephadex G25 size-exclusion chromatography of water soluble EG alkane 
phosphoserine capped SPIONs. SPIONs were subjected to Sephadex G25 chromatography 
after the first incubation with EG alkane phosphoserine ligand (Section 3.2.3). Images of (A) 
the SPIONs on the column and (B) the SPIONs that eluted from the column in the excluded 
volume, V0. 
 
EG alkane phosphoserine capped SPIONs that eluted at V0 from the G25 column were 
subjected to DEAE and CM ion-exchange chromatography (Fig. 3.5A). All of the SPIONs were 
eluted from the DEAE and CM resin with water (Fig. 3.5B) and no SPIONs were detected on the 
DEAE or CM resin after the water washes (Fig. 3.5C). This shows that the EG alkane 
phosphoserine capped SPIONs were neutral in charge  and that the EG alkane phosphoserine  
ligand forms a ligand shell that is sufficiently closely packed to prevent access of the anime and 
carbonyl groups on these resins from binding to the iron oxide core of the SPIONs.  
A                                      B                                     C 
 
Figure 3.5 Chromatography of EG alkane phosphoserine capped SPIONs on ion-exchange 
chromatography resins. After the final incubation with EG alkane phosphoserine ligand, 
SPIONs were transferred to water and concentrated and then subjected to DEAE anion-
exchange and CM cation-exchange chromatography (Section 3.2.4). Images were acquired of 
(A) the SPIONs on the DEAE and CM resins, (B) the SPIONs washed from the resins with the 
water and (C) of the DEAE and CM resins after the water washes. 
CM 
DEAE CM DEAE CM DEAE 
CM CM DEAE DEAE DEAE 
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3.3.3 Decomposition of SPIONs in the citrate assay. EG alkane phosphoserine capped SPIONs 
that passed through all of the chromatography resins were used in a citrate assay to 
investigate the decomposition of the core materials of the nanoparticles.  
 
Figure 3.6 Dissolution of SPIONs in citrate at different pHs. SPIONs were incubated with 
sodium citrate at pH 7.14, pH 5.5 and pH 4.5 for the numbers of days indicated before adding 
Ferrozine reagent. The percentage dissolution of the SPIONs was then determined by 
measuring the amount of Fe3+ ions in solution using the UV-vis absorbance of Ferrozine 
chelated to Fe3+ at 590 nm. 
EG alkane phosphoserine capped SPIONs were incubated with sodium citrate at pH 7.14, pH5.5 
and pH 4.5 over a course of 9 days. Samples were tested on a daily basis to measure the 
concentration of Fe3+ ions in the solution as an indication of the amount of dissolution of the 
SPION core. As the pH of the sodium citrate buffer decreased, the dissolution of the SPIONs 
increased (Fig. 3.6), showing that the SPIONs decompose much more quickly in acidic 
environments in the presence of citrate. At pH 7.14 and 5.5 only a small increase in dissolution 
of the SPION cores was observed over the first two days. In contrast, at pH 4.5, a more 
substantial decomposition of the materials was apparent one day after addition of the citrate 
buffer (Fig. 3.6). 
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3.4 Discussion 
The concept of the ligand shell as ‘head’, ‘stem’ and ‘foot’ has proved useful in the design of 
the EG alkane phosphoserine ligand for SPIONs.  It gives rise to the possibility of being able to 
impart the same biological and chemical stability, as seen with EG alkanethiol capped noble 
metal nanoparticles and QDs (Chapter 2), to any nanomaterial by using the same ‘head’ (in this 
case, EG) and ‘stem’ (in this case, alkane), but by changing the ‘foot’, which is required to 
exchange with the ligands used in synthesis and to anchor the ligand to the nanoparticle. With 
this in mind, a new ‘foot’ was designed for the existing ‘head’ and ‘stem’ of the ligand shell and 
the new ligand was synthesised, as shown in the schematic (Schemes 3.2.1 and 3.2.2), from 
the EG alkane thiol ligand used for the QDs. 
The ‘foot’ for the new ligand was phosphoserine and was chosen based upon the fact that this 
would allow conjugation to the iron oxide surface via phosphate and carboxyl functional 
groups. Both carboxyls and phosphates have previously found success as molecules for 
anchoring ligands to the surface of SPIONs in organic solvents (Sahoo et al. 2001, Bourlinos et 
al. 2002, Zhang et al. 2006, Vo et al. 2009), although there are limited examples available in 
the literature of phosphates being used in this way compared to carboxyls. However, 
phosphates and phosphonates are known to bind to Fe3+ ions. For example, the function of 
phosphates as scale control agents in water treatment can be adversely affected by the 
presence of Fe3+ due to their binding (Amjad 2002). Furthermore, for the same reason, Fe3+ 
interaction with apo-transferrin in vitro has been shown to decrease at high phosphate 
concentrations (Hilton et al. 2012). 
The SPIONs that were chosen for these experiments were coated in oleic acid and so the 
ligands were anchored via a carboxyl group.  They were deemed to be an appropriate starting 
material for ligand-exchange with the EG alkane phosphoserine ligand. This is because it was 
thought that the addition of the aqueous phase during the ligand-exchange reaction would be 
sufficient to remove enough of the highly hydrophobic oleic acid ligands from the surface of 
the SPIONs to allow the adsorption of the EG alkane phosphoserine.  Moreover, the outgoing 
oleic acid ligands would be unlikely to displace the incoming ligands again due to their low 
concentration and that the EG alkane phosphoserine ligand is likely anchored by two 
functional groups, meaning that it has a competitive advantage. Finally, the SPIONs were 
soluble in toluene and as for the QDs they were miscible in THF. 
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The longer incubation times and higher concentration of incoming ligand that was required to 
achieve successful ligand-exchange for the SPIONs compared to the QDs suggest that the 
interactions between the SPION surface and the carboxyl group of the oleic acid may be more 
stable than the interactions between the ZnS shell of the QDs and the amine groups of the 
ODA. This is, perhaps, understandable, due to the fact that carboxyls attach to the SPIONs 
through both of the oxygen atoms in the functional group (Zhang et al. 2006), whereas the 
amine will only attach to the QD surface through one atom and also, because of the ability of 
the oxygens in the carboxyl group to behave as bidentate ligands and chelate the iron (Zhang 
et al. 2006). 
After ligand-exchange, as previously seen with the QDs, all visible SPIONs were able to pass 
through Sephadex G25, and DEAE and CM Sepharose without binding to the resin. This means 
that the ligand-exchange reaction on the SPIONs produced SPIONs with a robust enough EG 
alkane phosphoserine ligand shell so as to avoid non-specific binding in these stability tests. 
However, it seems that the SPIONs ligand shell may be slightly superior to that of the QDs in 
that no SPIONs were seen to attach to the DEAE resin and were all washed off with water 
rather than just the majority of them. It is possible that attachment of a small proportion of 
the SPIONs to any of these resins would go undetected, due to their light colour when diluted. 
On the other hand, with the quantum dots being so intensely fluorescent due to their high 
quantum yield, even a small amount of residual QDs left behind on a column gives enough of a 
fluorescent signal for detection to be possible.  
SPIONs have an application in biological imaging, because they can be used to enhance 
contrast in MRI. An important advantage of the EG alkane phosphoserine capped SPIONs  is 
that the ligand shell is thin and thus will not shield water protons from the magnetic moment 
of the SPION, ensuring maximal contrast enhancement. One proposed application of SPIONs is 
to track cells loaded with SPIONs after transplantation in vivo. For this to happen, cells must be 
loaded with enough SPIONs to give a large enough signal for detection and must remain in the 
cells long enough for extended periods of cell tracking to take place. Moreover, for general 
MRI contrast enhancement, a very stable SPION that was excreted rather than rapidly 
metabolised might be of some advantage. Therefore, EG alkane phosphoserine capped SPIONs 
that passed through all three chromatography resins were tested in a citrate chelation assay, 
which is analogous to the DTT ligand exchange test used with QDs (Section 2.4). In the citrate 
chelation assay, the dissolution of the SPION by chelation of Fe ions is measured. By 
performing the assay at neutral and acid pH, good indication of the degradation of SPIONs in 
acidic cellular compartments such as endosomes and lysosomes can be obtained. This is 
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important, because it seems that most nanoparticles will enter the cell through endosomes 
before ending up in lysosomes. The citrate assay is also a good indicator of the integrity of the 
ligand shell of the SPIONs as robust enough to prevent the leeching of Fe ions from the core of 
the nanomaterials. At pH 7.14 and pH 5.5, the SPION cores seem to be quite resistant to 
degradation for a few days following addition of the citrate buffer, since there is little increase 
in dissolution up to day 2. This suggests that they might be suitable for short term 
internalisation in cells and compartmentalisation into endosomes. However, the more rapid 
dissolution at pH 4.5 means that when the SPIONs enter into the lyosomal pathway, they are 
likely to dissolve progressively into Fe ions and be cleared from the cells. However, ion 
chelation molecules in lysosomes are much larger than citrate and so the present SPIONs may 
have a longer lifetime in the lysosome than suggested in this in vitro assay.  
For all pHs tested, there was a progressive decomposition of the SPION cores, although much 
more slowly for pH 7.14 and pH 5.5 than for pH 4.5. This could point to a problem with the 
integrity of the ligand shell. One issue could be that, for the size of the nanoparticles that have 
been used, only 50% of the core contains the type of iron oxide with Fe3+ (Park et al. 2004) . 
Fe3+ would potentially allow better packing of the ligand shell since one phosphate would 
interact with every iron atom. For Fe2+, on the other hand, 3 iron atoms are required for every 
2 phosphates, which means that fewer ligands would conjugate to the nanoparticle, thus 
producing a less robust ligand shell.  If this is the problem, a simple remedy would be to use 
smaller iron oxide nanoparticles, which have been shown to have a higher content of the type 
of iron oxide that is made of Fe3+(Park et al. 2004). In addition, the ligand exchange protocol 
may require further refinement. Finally, the ‘foot’ of the new ligand may not be the optimum 
size of shape to allow sufficient packing of the ‘stem’ of the ligands to produce a dense enough 
ligand shell to prevent the citrate from accessing the core of the SPIONs and causing the 
decomposition. In this case, an alternative foot, ranging from just phosphate to other phospho 
amino acids, may resolve the problem. 
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Chapter 4 
Conclusions and Perspectives 
4.1 Conclusions 
Self-assembled ligand shells have proven to be very successful in the application of noble 
metal nanoparticles to real biological problems. For example, the Mix-matrix ligand shell 
developed for gold nanoparticles produces nanoparticles with incredibly low non-specific 
binding that could be stoichiometrically functionalised (Duchesne et al. 2008, Duchesne et al. 
2012) and has allowed a radically new view of the pericellular matrix from their use in 
biological experiments (Duchesne et al. 2012). This work on noble metals led to the hypothesis 
that nanoparticle stability is largely due to tight packing of the ligands, which is also evidenced 
by the lack of access to the noble metal nanoparticle itself by small molecules such as 
dithiothreitol (Chen et al. 2012), with the ethylene glycol units imparting colloidal stability. 
Thus, adaptation of the “foot”, which serves to anchor the ligand to the nanoparticle, would 
allow similar stabilisation of other nanoparticles.  This hypothesis was tested here with two 
different nanomaterials. 
The thiol of the EG alkanethiol ligand that was used for the gold was also suitable for use with 
the QDs. It is clear that the present approach has successfully produced the first small 
hydrodynamic radius QDs with a ligand shell that is both robust and simple to functionalise for 
biological experiments. In contrast, iron oxide has different ligand binding properties and so 
SPIONs can be regarded as a real critical test of the hypothesis. The EG alkane phosphoserine 
ligand was very successful, particularly if we consider that greater stability may be achieved by 
controlling the ratio of Fe2+ to Fe3+, further optimising ligand exchange parameters and testing 
ligands with variations in their different elements.   
Therefore, the hypothesis that SAMs of small ligands are a most effective route to the 
synthesis of nanomaterials that are really suitable for biological applications is sustained. 
 72 
4.2 Future work 
4.2.1 QDs 
Future work for the QDs would include using the present FGF2-QDs to understand the 
transport, receptor assembly and fate of FGF-2.  For transport, they could be used in 
experiments in extracellular matrix and perhaps even in more complex organotypic cultures, 
for example embryonic lung explants (Jesudason et al. 2006).  The stoichiometry and dynamics 
of assembly of the FGF receptor signalling complex would be another area where the quantum 
dots would provide valuable new insights. The photostability of the QDs would allow 
experiments that aimed to establish the order of assembly of the different components (FGF 
ligand, FGF receptor and heparan sulfate co-receptor) and the subsequent fate of the 
signalling complex.  While such complexes are universally endocytosed, there are major 
questions, including the balance between the degradation of the components in the lysosome 
and their recycling to the cell surface. Moreover, FGF-2 is unusual, because some of the ligand 
traffics to the nucleus after receptor-mediated endocytosis (Fernig & Gallagher 1994).  
Determining if the FGF2-QDs also trafficked to the nucleus would not just impact on FGF 
biology, but would also provide a means to deliver large cargo to the intracellular space.  
Another consideration would be to expand the capacity for coupling functional molecules to 
the QDs in order to increase the opportunity of application of these nanomaterials. In this 
work, the QDs with FGF2 were functionalised via a Tris-NTA linker and with kinesin via a 
streptavidin linker attached to COOH functionalised ligands on the surface of the QDs. This 
should already allow the functionalisation of the QDs with other his-tagged or biotinylated 
functional molecules or those that have a targetable amine. A selection of these types of 
proteins could be tested to see if they are also successful with these QDs. Alternatively, 
conjugation of the QDs to antibodies means that the QDs could be used in 
immunohistochemistry assays or in the detection of pathogens, or conjugation of the QDs to 
nucleic acids could expand their applicability to microarrays or DNA probes. Finally, the 
genetically encoded routes to couple molecules to QDs currently only include the 6xhis tag and 
ways to extend this would increase the versatility of the probe. Possibilities include the various 
commercially available “snap tags”. These encode a fusion partner for a recombinant protein 
that reacts covalently with a substrate on the probe, such as the “Halotag” system sold by 
Promega.  The challenge would be to incorporate the substrate onto the QDs. 
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4.2.2 SPIONs 
Future work for the SPIONs would initially require synthesising a range of ligands centred 
around the EG alkane phosphoserine described in Chapter 3.  These could include replacing 
the phosphoserine with phosphotyrosine and phosphohistidine, since these other side chains 
on their own interact with iron oxide and they have a different shape to serine.  The simplest 
ligand would have an alkane chain terminated by a phosphate and this should also be tested, 
as it may pack the most efficiently.  Longer and shorter lengths of alkyl chains could also be 
used in this set of ligands, e.g., nine and thirteen methyl groups, in addition to the eleven used 
here, as this will influence ligand packing and may improve stability, particularly in the citrate 
chelation assay at low pH.  Some examples are detailed below in Scheme 4.1. Finally, if the 
SPIONs are to be used at high concentration, they may require longer EG units to prevent 
aggregation due to their magnetism. Alongside this work, a more in depth analysis of the 
parameters governing ligand exchange would be useful, as this on its own my improve SPION 
stability significantly. In this way, SPIONs that are more stable at low pHs, as tested in the 
citrate assay, should be produced. Once the ligand shell has been fully optimised, 
functionalisation of SPIONs can commence or alternative mechanic methods of internalisation 
of the SPIONs in cells can be tested like magnetotransfection, cell scraping or osmotic loading. 
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Figure 4.1. Possible ligands to test for stabilisation of SPIONs based on the current EG alkane 
phosphoserine ligand. 
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Figure 1. DLS of EG alkanethiol capped QDs to determine the hydrodynamic radius. 
 
 
450 500 550 600 650 700 750
0
100
200
300
400
500
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 (
A
U
)
Wavelength
 NN-Labs raw materials
 EG alkanethiol capped QDs
 
Figure 2. Fluorescence intensities of QDs before and after ligand-exchange with EG 
alkanethiol ligands. Both samples had an optical density of 0.2 at 600 nm. The integrated 
areas underneath each curve are detailed in the figure. Relative quantum yield was 
calculated using the ratios of the areas underneath each curve and the known quantum yield 
of NN-Labs QD as 40%.  
Area = 13158.93168 
 
Area = 9333.016343 
 
